US Clinical Development and Medical Affairs -General Medicine
AIN457/S ecukinumab
Clinical Trial Protocol CAIN457AUS02 / [STUDY_ID_REMOVED]
A randomized, double- blind, placebo -controlled, parallel -
group, multicenter study to ev aluate the effect of 
secukinumab on aortic v ascular inflammation and 
cardiometabolic biomarkers after [ADDRESS_390937] s with moderate to se vere 
chronic plaque -type psoriasis
Document type: Amended Protocol Version
Version number: v03 ( Clean )
Development phase: IV
Release date: 27-Feb-2018
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed 
without the consent of [COMPANY_001]
Clinical Trial Protocol Template Version 2.0, November , 2013

[COMPANY_001] Confidential Page 2
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390938] of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 9
Amendment 3 .................................................................................................................... 10
Protocol summary .............................................................................................................. 11
1Introduction ....................................................................................................................... 17
1.1 Background ............................................................................................................ 17
1.2 Purpose .................................................................................................................. 18
2Study  objectives ................................................................................................................. 18
2.1 Primary  objective(s) ............................................................................................... 18
2.2 Secondary  objec tives ............................................................................................. 18
18
3Investigational plan ........................................................................................................... 19
3.1 Study  design ........................................................................................................... 19
3.1.1
Screening period (Screening to randomization).................................... 19
3.1.2
Double- blind treatment period (Randomization through Week 12 pre -
dose) ...................................................................................................... 20
3.1.3
Double-blind induction period (Week 12 dose through Week 15 dose) 21
3.1.4 Open -label treatment period (Week 16 through Week 52) ................... 21
3.2 Rationale of study  design ....................................................................................... 22
3.3 Rationale of dose/regimen, route of administration and duration of treatment .....23
3.4
Rationale for choice of comparator ....................................................................... 23
3.5 Purpose and timing of interim anal yses/design adaptations .................................. 23
3.6 Risks and benefits .................................................................................................. 23
4Population .......................................................................................................................... 27
4.1 Inclusion criteria .................................................................................................... 27
4.2 Exclusion criteria ................................................................................................... 28
5Treatment ................................ ................................ ................................ ........................... 31
5.1 Protocol requested treatment ................................................................................. 31
5.1.1 Study  treatment ..................................................................................... 31

[COMPANY_001] Confidential Page 3
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390939] demographics/other baseline characteristics............................................. 49
6.2.1 Demographics ....................................................................................... 49
6.2.2 Psoriasis history  / Prior psoriasis therapi[INVESTIGATOR_014]
........................................... 49
6.2.3 Smoking history .................................................................................... 49
6.2.4 Alcohol use history ............................................................................... 50
6.2.5 Comorbidities –cardiovascular history ................................................ 50
6.2.6 Relevant medical history / Current medical conditions ........................ 50
6.2.7
Prior and concomitant medications....................................................... 50
6.2.8 Determination of tuberculosis status ..................................................... 50
6.2.9 Other baseline characteristics ................................................................ 52
6.3 Treatment exposure and compliance ..................................................................... 52
6.4 Efficacy .................................................................................................................. 52

[COMPANY_001] Confidential Page 4
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
6.4.1 Target (arterial vascular uptake) to background (venous blood pool) 
ratio from the aorta................................................................................ 53
6.4.2 Cardi ometabolic biomarkers ................................................................. 54
6.4.3 Assessment of total body surface area (BSA) and Psoriasis Area and 
Severity  Index (PASI )
........................................................................... 55
6.4.4 Investigator’s Global Assessment (IGA mod 2011) ............................. 57
6.4.5 Health
-related qualit y of life (HRQ oL)................................................. [ADDRESS_390940] demographics and other baseline characteristics...................................... 68
9.3 Treatments ............................................................................................................. 68
9.4 Analy sis of the primary  variable ............................................................................ 69
9.4.1 Variable ................................................................................................. 69

[COMPANY_001] Confidential Page 5
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 69
9.4.3 Handling of missing values/censoring/discontinuations ....................... 69
9.4.4 Supportive analy ses............................................................................... 69
9.5 Analy sis of secondary  variables
............................................................................ 70
9.5.1 Efficacy  variables
.................................................................................. 70
9.5.2 Safety
 variables ..................................................................................... 70
9.5.3 Resource utilization ............................................................................... 71
9.5.4 Pharmacokinetics .................................................................................. 71
9.5.5 Pharmacogenetics/pharmacogenomics ................................................. 71
9.5.6 Other biomarkers ................................................................................... 71
9.5.7 PK/PD ................................................................................................... 71
9.6 Interim anal yses..................................................................................................... 71
9.7
Sample size calculation.......................................................................................... 71
10Ethical considerations ................................ ................................ ................................ ........ 71
10.1 Regulatory and ethical compliance ........................................................................ 71
10.2 Informed consent procedures
................................................................................. 72
10.3 Responsibilities of the investigator and IRB/ IEC.................................................. 72
10.4 Publication of study  protocol and re sults............................................................... 73
11Protocol adherence ................................ ................................ ................................ ............ 73
11.1 Protocol Amendments ........................................................................................... 73
12References ................................ ................................ ................................ ......................... 73
13Appendices ........................................................................................................................ 76
13.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 76
13.2
Appendix 2: Tuberculosis screening flowchart ..................................................... 77
13.3 Appendix 3: Psoriasi s Area and Severity Index (PASI ) and Body  Surface Area 
(BSA) ..................................................................................................................... 78
13.4 Appendix 4: I nvestigator’s Global Assessment (IGA mod 2011)
......................... 79
13.5 Appendix 5: Dermatology  Life Qualit y Index (DLQI) ......................................... [ADDRESS_390941] of tables
Table 3
-1 Clinical outcomes at Week 12 in adults with plaque psoriasis in Trials 
1 and 2 ................................ ................................ ................................ ...25
Table 3-2 Clinical outcomes at Week 12 in adults with plaque psoriasis in Trials 
3 and 4 ................................ ................................ ................................ ...25

[COMPANY_001] Confidential Page 6
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390942] of figures
Figure 3 -
1 Study  design .......................................................................................... 22

[COMPANY_001] Confidential Page 7
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390943] of abbreviations
AE adverse event
ALT(SGPT) alanine aminotransferase
ANCOVA Analy sis of covariance
AST (SGOT) aspartate aminotransferase
BSA Body Surface Area
CFR US Code of Federal Regulations 
eCRF electronic Case Report Form
CRO Contract Research Organization
CV cardiovascular
DICOM Digital Imaging and Communication in Medicine
DLQI Dermatology  Life Quality  Index
DS&E Drug Safet y & Epi[INVESTIGATOR_317572] -PET/CT [18F] -fluorodeox yglucose positron emission tomograph y with computer 
assisted tomograph y
GCP Good Clinical Practice
hCG h
uman chorionic gonadot r opin
HDL high-densit y lipoprotein
HIV human immunodeficiency virus
HRQoL Health
-related Quality  of L ife
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IFU Instructions for Use (secukinumab)
IGA mod 2011 [COMPANY_001] Investigator’s Global Assessment modified 2011

[COMPANY_001] Confidential Page 8
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390944] (raised serum transaminases and/or bilirubin levels)
LOCF Last-observation -carried- forward
MedDRA Medical dictionary  for regulatory  activities 
MRI magnetic resonance imaging
MTX methotrexate
OC/RDC Oracle Clini cal/Remote Data Capture
OTC over-the-counter
PASI Psoriasis Area and Severity  Index
PFS prefilled s yringe
PUVA psoralen ultraviolet A
SAE serious adverse event
s.c. subcutaneous
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
SUV standardized uptake value
TB tuberculosis
TBR target to background ratio
TCS topi[INVESTIGATOR_317573] A
UVB ultraviolet B
WBC white blood cells
WHO World Health Organization 

[COMPANY_001] Confidential Page 9
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_37214] A group of newly enrolled patients treated at a specific dose and 
regimen (i.e. treatment group) at the same time
Control drug Any drug (an active drug or an inactive drug, such as a placebo) 
which is used as a comparator to the drug being tested in the trial
Dose level The dose of drug given to the patient (total daily or weekly  etc.)
Enrollment Point/time of patient entry into the study at which informed consent 
must be obtained (i.e. prior to starting a ny of the procedures described 
in the protocol)
Medication number A unique identifier on the label of each investigational/study drug 
package in studies that dispense medication using an IRT sy stem
Protocol A written account of all the procedures to be followed in a trial, which 
describes all the administrative, documentation, analytical and clinical 
processes used in the trial.
Period A portion of the study which serves a specific purpose. T ypi[INVESTIGATOR_317574]: screening/recruitment, wash -out, treatment , and follow -up
Premature subject/patient 
withdrawalPoint/time when the patient exits from the study prior to the planned 
completion of all study treatment administration and/or assessments; 
at this time all study treatment administration is discontinued and no 
further assessments are planned, unless the patient will be followed 
for progression and/or survival
Randomization number A unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Study drug Thedrug whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is s ynon ymous with 
“investigational new drug” or “investigational medicinal product.”
Study treatment All investigational drug(s) whose pr operties are being tested in the 
study as well as their associated treatment controls. 
This includes any placebos, any active controls, as well as approved 
drugs used outside of their indication/approved dosage or tested in a 
fixed combination. 
Investigational treatment generally does not include protocol -specified 
concomitant background therapi[INVESTIGATOR_317575]/time when patient permanently stops taking study treatment  for 
any reason; may  or may  not also be the point/time of premature 
patient withdrawal
Subject Number A num ber assigned to each patient who enrolls into the study 
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being 
tested in the study

[COMPANY_001] Confidential Page 10
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390945] 
cardiometabolic biomarkers:
Protocol Summary
Section 2.2
Section 6.4
Section 6.4.[ADDRESS_390946] 
(IRBs)/Independent Ethics Committees (I ECs) and Health Authorities as required.
.

[COMPANY_001] Confidential Page 11
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390947] of secukinumab compared to placebo on 
aortic vascular inflammation in subjects with moderate to severe plaque 
psoriasis
Sponsor and Clinical 
Phase[COMPANY_001] / Phase IV
Investigation type Drug
Study type Interventional
Purpose and rationale Secukinumab targets Interleukin 17a (IL-17a), which is increasingly 
understood to be a critical component of the pathophy siology  of psoriasis ,
and evolving research also suggests that IL-[ADDRESS_390948] to aortic vascular inflammation at 
12 weeks of treatment, and up to 52 weeks of treatment in subjects with 
moderate to severe plaque psoriasis.
Primary Objective(s) To evaluate the effect of secukinumab compared to placebo on aortic 
vascular inflammation with respect to the change from baseline in the 
target (arterial vascular uptake) to background (venous blood pool) ratio 
from the aorta
Secondary Objectives To evaluate the effect of secukinumab compared to placebo with 
respect to change from baseline in cardiometabolic biom arkers 
(cardiometabolic function [lipid particle size, HDL function 
(cholesterol efflux)], measures of inflammation [TNF -Alpha, IL-6, C-
reactive protein , GlycA ], adiposity [leptin and adiponectin], insulin 
resistance [insulin levels/glucose to yield HOMA -IR], and markers 
predictive of diabetes [apolipoprotein B, ferritin, IL-2 receptor A, IL-
18, and fetuin -A]) at W eek 12
To evaluate the effect of secukinumab compared to placebo in 
subjects with moderate to severe chronic plaque -type psoriasis with 
respect to change from baseline in the PASI 75, 90 and 100 
response rates at W eek 12
To evaluate the effect of secukinumab compared to placebo in 
subjects with moderate to severe chronic plaque -type psoriasis with 
respect to the Investigator’s Global Assessment mod 2011 (IGA mod 
2011) 0 or 1 response at W eek 12

[COMPANY_001] Confidential Page 12
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
To evaluate the effects of secukinumab compared to placebo with 
respect to change from baseline in the Dermatol ogy Life Quality 
Index (DLQI) total score at W eek 12
To evaluate the clinical safety  and tolerability of secukinumab as 
assessed by [CONTACT_18651], clinical laboratory variables, and adverse 
event monitoring
Study design This is a randomized, double -blind, placebo -controlled, parallel -group, 
multicenter study  in approximately 84 subjects with moderate to severe 
plaque psoriasis. The study consists of four periods:  Screening (from 1 
to 4 weeks); Double -blind Treatment Period (12 weeks); Double -blind 
Induction Period (4 weeks); and Open -label Treatment Period (36 
weeks).
At Visit 2, eligible subjects will be randomized in a 1:1 ratio to one of two 
treatment groups –secukinumab or placebo. At the end of the Double -
blind Treatment Period, all subjects receiving placebo will be switched to 
secukinumab treatment for the remainder of the study . 
Population The study population will consist of male and female subjects at least 18 
years of age with moderate to severe plaque -type psoriasis who are
candidates for sy stemic therapy or phototherapy .
Inclusion criteria Provide written, signed and dated informed c onsentbeforeany study-
related activity i s performe d; where relev ant, a legal repres entativ e will
also sign the informe d study consent according to local laws an d 
regul
ations
Males and females ≥18 years of age at time of screening
Clinical diagnosis of chronic plaque -type psoriasis at least [ADDRESS_390949] interview of his/her 
medical histor y and confirmation of diagnos is through physical 
examination by [CONTACT_737]
Moderateto severe pl aque psoriasis asdefinedatBaseline by:
o≥10% Body Surface Area (BSA) involvement and
oPASI score of ≥12 and
oIGA mod 2011 score of ≥3 (based on a scale of 0 – 4)
Candidate for systemic therapy, defined as having plaque psoriasis 
inadequately controlled by:
[CONTACT_317592][INVESTIGATOR_131525]/or
ophototherapy and/or
oprevious s ystemic therapy
Physical examination and FDG -PET/CT scan without clinically 
significant findings that would meaningfully alter the risk-benefit 
profile of secukinumab in the Investigator’s opi[INVESTIGATOR_1649], and clinical 
laborator y results within laboratory reference ranges, or abnormal 
results that are deemed to be not clinically significant by [CONTACT_317593] 13
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Exclusion criteria Forms of diagnosed psoriasis ot her t han chronic plaque psoriasis
(e.g., e rythrodermic, generalized or localized pustular psoriasis, or new 
onset guttate psoriasis)
Previous exposure to secukinumab or any other biologic drug directly 
targeting IL-17A or IL-17RA receptors (e.g., ixekizumab, or 
brodalumab)
Diagnosis of other active ongoing skin diseases or skin infections 
(bacterial, fungal, or viral), or inflammatory  diseases other than 
psoriasis that may interfer e with the evaluation of psoriasis
Ongoing use of pr ohibited psoriasis tr eatm ents (e.g., topi[INVESTIGATOR_317576] c corticosteroids, other topi[INVESTIGATOR_5910], systemic 
psoriasis treatments oral or biological, UV therapy)
Women o f child- bearing potential not using effective met hods of 
contraception , pregnan t ornursin g women
Positive serology for human immunodeficiency  virus (HIV) , hepatitis
B or C infection, or known history  ofother severe, recurrent or 
persistent infections
Any unde rlying condition which significantly immunocompromise s 
the subject and/or place s the subje ctatunaccep tabl e risk for
receiving an immunom odulato rytherapy
History of an ongoin g,chronic or r ecurrent infectio usdiseas e,or
evidenceof tuberculosi s infection
Plans for administration of live vaccines during the study  period or 6 
weeks before randomization
Study drug and control 
drugStudydrug:
Secukinumab, liquid formulation in a prefilled syringe (PFS) for 
subcutaneous injection
Control drug :
Placebo to secukinumab, liquid formulation in a prefilled syringe 
(PFS) for subcutaneous injection
Efficacy  assessments Target (arterial vascular uptake) to background (venous blood pool) 
ratio from the aorta as measured by [CONTACT_6789] -PET/CT
Cardiometabolic biomarkers : (cardiometabolic function [lipid particle 
size, HDL function (cholesterol efflux)], measures of inflammation 
[TNF -Alpha, IL -6, C-reactive protein , GlycA], adiposity [leptin and 
adiponectin], insulin resistance [insulin levels/glucose to yield HOMA -
IR], and markers predictive of diabetes [apolipoprotein B, ferritin, IL -2 
receptor A, IL -18, and fetuin -A])
PASI: Psoriasis Area and Severity Index
IGA mod 2011: Investigator’s Global Assessment modified 2011

[COMPANY_001] Confidential Page 14
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
DLQI: Dermatology Life Quality Index
Safety assessments Adverse events and serious adverse events
Laboratory assessments (e.g., hematology, clinical chemistry , viral 
serology, serum and urine pregnancy)
Vital signs, physical examination
Data analysis A designated Contract Research Organization will perform the statistical 
analysis.
It is planned that the data from all centers that participate in this protocol 
will be combined, so that an adequate number of subjects will be 
available for analy sis.
Unless otherwise specified, all statistical tests will be conducted against a 
two-sided alternative hypothesis, employing a significance level of 0.05.
The following analy sissets will be used for the statistical reporting and 
analyses:
Randomized Set: The randomized set includes all subjects who were 
randomized.
Safety Set: The Safety Set includes all subjects who received at least one 
dose of study medication. Subjects will be analyzed according to 
treatment received.
Full Analysis Set:  The Full Analy sis Set includes all subjects to whom 
study medication has been assigned. Subjects inappropriately 
randomized (e.g., IRT was called in error for randomization of a screen 
failed subject) will be excluded from this analysis set.  
Data will be summarized with respect to demographic and baseline 
characteristics for the Randomized Set and the Full Analy sis Set.
Concomitant medications will be summarized by [CONTACT_317594].
Efficacy , safety, and other data will be summarized.
The primary  efficacy  variable is the change from baseline in the target 
(arterial vascular uptake) to background (venous blood pool) ratio from 
the aorta. Target to background ratio is considered the standard reporting 
variable based onFDG -PET/CT scans in vascular studies (see Section 
6.4.1 ). The primary  analysis time point will be at Week 12.
The primary efficacy variable will be analy zed by [CONTACT_317595] (ANCOVA) model with treatment, baseline, and body  weight 
(<90 kg, ≥90 kg) as explanator y variables. The least squares meansof 
the two treatment groups , least squares mean difference of the treatment 
groups, 95% confidence interval for the difference in the two treatment 
groups, and p-value based on the fitted linear model will be reported.  
Missing data will be imputed using the last-observation -carried -forward 
(LOCF) method. If a subject has no post-baseline value, the missing 
value will not be imputed and the subject will be removed from the 

[COMPANY_001] Confidential Page 15
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390950] with modified ridit scores (van Elteren’s test), adjusting for 
body  weight (<90 kg, ≥90 kg) ( Stokes, Davis, and Koch, 2012 ).
The primary  analysis and supporting analysis of the primary efficacy 
variable will be based on the Full Analysis Set.
The secondary efficacy  variables are the following:
• Change from baseline in each biomarker (see Section 6.4 )
• PASI 75 response (yes, no)
• PASI 90 response (yes, no)
• PASI 100 response ( yes, no)
• IGA mod 2011 score of 0 or 1 (yes, no)
• Change from baseline in DLQI total score
Change from baseline in each biom arker and change from baseline in 
DLQI total score will be analyzed at each time point using the same 
ANCOVA model as for the primary  efficacy  variable, and missing data will 
be im puted using the LOCF method.
IGA mod 2011 score of 0 or 1and PASI 75 / 90 /[ADDRESS_390951] to 
compare secukinumab and placebo, adjusting for body weight (<90 kg, 
≥90 kg) (Stokes, Davis, and Koch, 2012 ). A 95% confidence interval for 
the difference between the two treatment groups in the proportion of 
subjects who are responders will be calculated using the normal 
approximation to the binomial distribution. For response (yes, no) at 
Week 12 (and other time points), a subject with a missing assessment 
will be considered as a responder (y es) if the subject meets the response 
criterion at the time of premature discontinuation from the study. 
Otherwise, the subject will be considered as a non -responder (no).
Analyses of the secondar y efficacy variables will be based on the Full 
Analysis Set.
The assessment of safety will be based mainly on the frequency of 
adverse events and laboratory data. Other safety  data (e.g., vital signs 
and special tests) will be considered, as appropriate.
Analysis of safety data will be based on the Safety Set.
The sample size was based on change from baseline in the target 
(arterial vascular uptake) to background (venous blood pool) ratio (TBR) 
from the aorta. Using a t-test, a clinically important mean treatment 
difference of 0.15, a (common) stand ard deviation (SD) of 0.196, an 
allocation ratio of 1:1, a two-sided 
significance level of 0.05, and a power 
of 0.90, it was determined that approximately 74 subjects (37 in each 

[COMPANY_001] Confidential Page 16
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
treatment group) are necessary  (nQuer y Advisor 7.0) (Bissonnette et al 
2013 ; Tawakol et al 2013 ). Without adjusting for multiplicity, the sample 
size of [ADDRESS_390952] 0.90 power for other 
biom arkers (see Section 6.4.2 ) if the treatment difference is 0.76 SD or 
smaller. The general threshold for clinical importance is 1 SD. Allowing 
for a loss to follow -up rate of 0.10, approximately 84 subjects (42 in each 
treatment group) will be randomized.
Key words Plaque psoriasis , vascular inflammation, secukinumab, biologic, 
monoclonal antibody

[COMPANY_001] Confidential Page 17
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390953] approximately  2% of the US population 
(National Psoriasis Foundation 2014 ).
Psoriasis is associated with defects in high-density lipoprotein ( HDL )function, insulin resistance, 
and increased aortic vascular inflammation as measured by [18F] -fluorodeoxy glucose positron 
emission tomograph y with computer assisted tomograph y (FDG -PET/CT )
. These changes found 
in FDG -PET/CT would be theequivalent to a decade of aging in an individual without psoriasis
(Mehta et al 2011) . Patients with moderate to severe psoriasis have an increased risk of 
myocardial infarction, stroke, and cardiovascular (CV) death independent of traditional risk 
factors (Gelfand et 
al 2006; Gelfand et al 2009; Mehta et al 2010 ; Ogdie et al 2015). 
Observational data suggest that immune 
modulation with methotrexate or TNF inhibitors can 
lower the risk of major cardiovascular events in this at- risk population (Roubille et al 2015 )
. 
Interleukin 17a (IL-17a; also known as IL-17) is increasingl y understood to be a critical 
component of the pathophy siology  of psoriasis and evolving literature suggests that IL-17 may 
also promote cardiovascu lar disease (Abbas et al 2015; Erbel et al 2014 ;Karbach et al 2014 ). 
Secukinumab is a r ecombinant high-a ff inity fu llyhuman monoclonal anti-human IL- 17A 
antib ody of the immun oglobulin (Ig) G1/κ-cla ss. S ecukinumab bind s to human IL- 17A a nd
neutra lizesthe b ioactivity of this cytokine. Secukinumab has demonstrated efficacy  in reducing  
psoriasis skin severity . Psoriasis skin severit y directly  relates to vascular inflammation and 
cardiovascular comorbidity (Naik et al 2015; Yeung et al 2013) . Moreover, IL -[ADDRESS_390954]  would benefit these key aspects of atherogenesis (Erbel et al 
2011).
As it has been demonstrated that psoriasis is an independent risk factor for myocardial infarction , 
cutting edge approaches have since been developed to measur ethe impact of psoriasis 
on 
pathway s known to be causally  related to vascular events (e.g., HDL function, aortic vascular 
inflammation). For example, the primary  outcome for this study  isaortic vascular inflammation 
as measured by [CONTACT_6789]-PET/CT which allows for the anatomical localization and measurement of 
CD68+ macrophage metabolic activity . 
Vascular inflammation is quantified using target to background ratio (TBR) which measures the 
PET signal in the aorta relative to background (i.e., venous blood pool) and is a widel y used 
metric. Aortic inflammation measured by  [CONTACT_6789] -PET/CT is reliable (operator independent) (Mehta 
et 
al 2012), strongl y predictive of future cardiovascular events (Figueroa et al 2013), and is 
highl y sensitive to changes from risk factor modification 
(statins) ( Tawakol et al 2013) to 
therapeutic lifesty le changes (Lee et 
al 2008 ) known to lower the risk of cardiovascular events. 

[COMPANY_001] Confidential Page 18
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Therefore, FDG -PET/CT represents an important method of measuring cardiovascular disease 
and risk.
1.[ADDRESS_390955] of longer-term treatment with secukinumab (up to 52 weeks) on aortic vascular 
inflammation .
2 Study  objectives
2.1 Primary  objective(s)
The primary  objective is to evaluate the effect of secukinumab [ADDRESS_390956] tothe change from baseline in the target (arterial 
vascular uptake) to background (venous blood pool) ratio from the aorta . The primary  analysis 
time point will be at Week 12.
2.2 Secondary  objectives
To evaluate the effect of secukinumab compared to placebo with respect to change from 
baseline in cardiometabolic biomarkers (cardiometabolic function [lipid particle size, HDL  
function (cholesterol eff lux)], measures of inflammation [TNF -Alpha, IL -6, C- reactive 
protein, Gly cA], adiposity  [leptin and adiponectin], insulin resistance [insulin levels/glucose 
to yield HOMA -IR], and markers predictive of diabetes [apolipoprotein B, ferritin, IL-2 
receptor A, IL-18, and fetuin -A]) at Week 12
To evaluate the effect of secukinumab compared to placebo in subject s with moderate to 
severe chronic plaque -type psoriasis with respect to change from baseline in the PASI  75, 90 
and 100 response rates at Week 12
To evaluate the effect of secukinumab compared to placebo in subject s with moderate to 
severe chronic plaque -type psoriasis with respect to the I nvestigator’s Global Assessment 
mod 2011 (IGA mod 2011) 0 or 1 response at Week 12
To evaluate the effects of secukinumab compared to placebo with respect to change from 
baseline in the Dermatology  Life Qualit y Index (DLQI) total score at Week 12
To evaluate the clinical safet y and tolerability of secukinumab as assessed by [CONTACT_18651], 
clinical laboratory  variables, and a dverse event monitoring

[COMPANY_001] Confidential Page 19
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390957] s with moderate to severe chronic plaque -type psoriasis will be 
randomized from approximately  10 investigative sites in the United S tates.
The study  consists of four periods:  Screening (from 1 to 4 weeks); Double-blind Treatment 
Period (12 weeks); Double -blind Induction Period (4 weeks); and Open -label Treatment Period 
(
36weeks). A schematic of the study design and visits is presente d in Figure 3
-1, while a detailed 
visit and assessment schedule can be found in Table 6 -1.
Safety , efficacy  and patient
-reported outcome (PRO) assessmen ts will be performed according to 
the visit schedule ( Table 6 -1).
All doses of study  treatment will be self-administered. Self-administration of the study 
treatment refers to subject self-injection or injection by a trained caregiver regardless of 
whether self-administration occurs at the study site or at home . Instruction and 
training will 
be provided b y site staff to subject s prior to self -injection.
3.1.1 Screening period (Screening to randomization)
The dura tion of the screening period will be up to four weeks (28 day s). Screening will be used to 
assess subject eligibility  and to taper subject s off prohibited medications and treatments.
[IP_ADDRESS] Visit 2 (Baseline)
Visit 2/Baseline should take place once all screening activities have been performed, and all 
results have been received and are confirmed to be within acceptable ranges for the subject to 
continue in the study . The Baseline visit should occur no later than 28daysafter the initiation of 
screening.
At Visit 2, all Visit 2/Baseline assessments indicated in Table 6-1should be performed with the 
exception of subject randomization via IRT and subject self-administration of study  treatment.
Subjects must notbe randomized until the clinical reading scan report from the FDG -
PET/CT has been received and reviewed to ensure there are no clinically important 
findings that would preclude a subject from continuing inthe study. Because the receipt of 

[COMPANY_001] Confidential Page 20
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
the report may take up to 24 hours , the Baseline visit is allowed tooccur over a two-day period
(+1 additional day  if needed) .
Once the scan report isreviewed and no clinically  important findings areidentified, the site 
should then proceed immediately  with subject randomization via IRT andadministration of the 
initial dose of study  treatment.
Ifthe FDG -PET/CT scan report does contain clinically  important findings, consultation with the 
Medical Monitor/appropriate medical experts and additional testing/work-up may be required to 
determine if the subject is eligible to continue in the study or must be discontinued . In these cases,
a +7-day window after the completion of the FDG -PET/CT scan is allowed to randomize and 
administer the first dose of study treatment.
3.1.2 Double -blind treatment period (Randomization through Week 12 pre -
dose)
The Double- blind Treatment Period is defined as Randomization through Week 12 (prior to the 
Week 12 dose). 
At the start of the Double -blind Treatment Period, eligible subject s will be randomized via 
Interactive Response Technology  (IRT) in a 1:1 ratio to one of two treatment groups 
(secukinumab 300 mg or placebo).   Subjects must be randomized and receive their first dose 
of study treatment no later than 7 days 
after the FDG -PET/CT scan.
Secukinumab : secukinumab 300 mg (two s.c. injections of the secukinumab 150 mg dose) 
once weekl y for five weeks (at Randomization, Weeks 1, 2, 3, and 4) followed b y a dose after 
four weeks at Week 8 (last dose during Double -blind Treatment Period).
Placebo: p lacebo (two s.c. injections of 150 mg secukinumab placebo per dose) once per 
week for five weeks (at Randomization, Weeks 1, 2, 3 and 4) followed b y a dose after four 
weeks at Week 8 (last dose during Double -blind Treatment Period).
During the Double- blind Treatment Period, all subject s will attend study  visits at Randomization, 
Weeks 1, 2, 3, 4, 8, and 12, and all doses of study  treatment will be self-administered at the 
study site .
Assessments for the primary  efficacy  variable will be performed at Week [ADDRESS_390958] s who discontinue study  treatment prematurel y for any reason before the end of 
Double- blind Treatment Period should return to the study  site for the performance of the Visit 
8/Week 12 End of Treatment 1 (EOT1) assessments. The EOT1 visit should be scheduled 28 
days(± 7 day s)after the last dose of study  treatment.
[IP_ADDRESS] Visit 8 (Week 12)
At Visit 8, all Visit 8/Week [ADDRESS_390959] notself-administer 

[COMPANY_001] Confidential Page 21
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
the Week 12 dose of study treatment until the clinical reading scan report from the FDG -
PET/CT has been received and reviewed to ensure there are no clinically important 
findings that would preclude a subject from continuing inthe study. Because the receipt of 
the report may take up to 24 hours, Visit 8/Week 12 is allowed to occur over a two-day period
(+1 additional dayif needed )
.
Once the scan report is reviewed and no clinically  important findings are identified, the site 
should then proceed immediately  with subject administration of the Week 12 dose and 
dispensation of the study  treatment for the Weeks 13, 14, and 15 at -home dosi ng.
If the FDG -PET/CT scan report does contain clinically  important findings, consultation with the 
Medical Monitor /other appropriate medical experts ,and additional testing /work -up may be 
required to determine if the subject is eligible to continue in the study  or must be discontinued. In 
these cases, a +7-day window after the completion of the FDG -PET/CT scan is allowed for the 
subject to administer the Week 12 dose .
3.1.3 Double -blind i nduction period (Week 12 dose through Week 15 dose)
All subject s who complete the Double- blind Treatment Period will enter the Double- blind 
Induction Period. 
During the Double -blind Induction Period, subject s randomized to placebo during the Double -
blind Treatment Period will be switched over to treatment with secukinumab [ADDRESS_390960] administer the Week 12 dose no later than 7 days after the Week 12 FDG -
PET /CT scan.
Secukinumab : Subject s who were randomized to the secukinumab treatment group at Visit 
2/Baseline will continue to self - administer secukinumab 300 mg (two s.c. injections of the 
150 mg dose) at Week 12. I n order to maintain the blind, these subjec ts will undergo a sham 
induction w ithweekly  placebo injections at Weeks 13, 14, and 15. 
Placebo: Subject s who were randomized to the placebo treatment group at Visit 2 /Baseline
will begin to self-administer secukinumab 300 mg (two s.c. injections of the secukinumab 150 
mgdose)weekl y for four weeks at Weeks 12, 13, 14, and 15.
Self-administration of the Week [ADDRESS_390961] at the study  site, while the doses at 
Weeks 13, 14, and 15 will be self -administered at home.
All subjects who discontinue s tudy treatment prematurel y for any reason before the end of 
Double- blind Induction Period should return to the study  site for the performance of the Visit 
14/Week 52 End of Treatment 2 (EOT2) assessments. The EOT2 visit should be scheduled 28 
days(± 7 day s) after the last dose of study  treatment.
3.1.4 Open -label treatment period (Week 16 through Week 52)
All subject s who complete the Double- blind Induction Period will enter the Open- label Treatment 
Period. The Open -label Treatment Period is defined as Week [ADDRESS_390962] s in 

[COMPANY_001] Confidential Page 22
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
the Open -label Treatment Period will receive secukinumab 300 mg s.c. at four-week intervals 
beginning at Week 16 through Week 48 (last dose during the Open -Label Treatment Period).
Self-administration of the doses at Weeks 16, 24, 32, 40, and 48will take place at the study  site; 
the doses at Weeks 20, 28, 36, and [ADDRESS_390963] s who discontinue study  treatment prematurely  for any reason before the end of the 
Open -label Treatment Period shou ld return to the study  site for the performance of the Visit 
14/Week 52 End of Treatment 2(EOT 2) assessments. The EOT 2visit should be scheduled 28 
days(± 7 day s)after the last dose of study treatment .
Figure 3
-1 Study  design
3.2 Rationale of study  design
The randomized, double -blind , placebo- controlled d esignused inthis studyisaligne d with
thePhaseIII tria ls ofsecukinumab, andwith previousstudies performed intheindication of
chronicplaquepsoria sis, andis in accorda ncewithhealth authority guidelines and feedback,
including theUnitedStates FoodandDrug Ad ministration (FDA). 
The study  population consists of adult subject s with moderate to severe plaque -type psoriasis 
who are candidates for s ystemic therap y or phototherap y. 
The primary  analysis time point of the trial is at Week 12. This is in line with the timing of the 
primary  analysis time point in the secukinumab Phas e III trials, and will allow for assessment of 

[COMPANY_001] Confidential Page 23
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390964] s randomized to receive placebo at Visit 2/Baseline , the 52-week treatment duration 
allows these subject s the opportunity  to receive up to 40weeks of treat ment with secukinumab.
Patients with moderate to severe psoriasis have a clinically  significant increased risk of major 
cardiovascular events and mortality  independent of traditional risk factors. Treatments that 
improve not only the skin manifestations of psoriasis but also its cardiovascular co-morbidities 
are of intense clinical and scientific interest. Measurement of aortic inflammation by [CONTACT_6789]-
PET/CT is a reproducible, operator independent, prognostic marker of future vascular events
(Figueroa et al 2013; Mehta et al 2012). Furthermore, it responds to statins and modulates in a 
short time frame (i.e.
, within 12 weeks) unlike alternative approaches such as carotid intima -
media thickness ( IMT)and MRI -based measures of wall thickness (Tawakol et al 2013 ).
3.3 Rationale of dose/regimen, route of administration and duration of 
treatment
Th
e proposal touse a dose of secukinumab 300 mg administered with a weekl y induction 
regimen for 
five weeks (at Randomization, Weeks 1, 2, 3, and 4) follo wed by[CONTACT_22058] t every 
four week s thereafte r (starting at Week 8 ) is in accordance with the current FDA -approved 
product labeling.
3.4 Rationale for choice of comparator
Due tothenature ofpsoriasis andtheoutcome m easures used for this indication , aplacebo arm
isnecess arytoobtain reliable effica cy m easurements. More over, the inclusion of aplacebo
gr
oup is in accordance with health authority guidelines and feedback (CHMP Psoriasis 
Guideline
-CHMP/EWP/2454/02 2004). The contin uation ofthe placebo group uptothe
primaryanalysis time point atWeek 12isin the study  design for the indication of chronic  
plaque -type psoriasis and is accepted by [CONTACT_268274], EMA and PMDA .
3.5 Purpose and timing of interim analy ses/design adaptations
The primary  analysis at Week [ADDRESS_390965] completed the Week 12 visit and the database is locked . As Week 12 is the primary 
analysis time point, no adjustment to the significance level of 0.05 will be made. See Section 5.4
on treatment blinding for additional information.
3.6 Risks and benefits
Secukinumab is currently  approved in the [LOCATION_002] for the treatment of moderate to severe 
plaque psoriasis in adult patients who are candidates fo r systemic therapy  or phototherapy .  
Four multicenter, randomized, double -blind, placebo
-controlled trials (Trials 1, 2, 3, and 4) 
enrolled 2403 subjects (691 randomized to secukinumab 300 mg, 692 to secukinumab 150 mg, 

[COMPANY_001] Confidential Page 24
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
694 to placebo, and 323 to a biolog ic active control) 18 years of age and older with plaque 
psoriasis who had a minimum body  surface area involvement of 10%, and Psoriasis Area and 
Severity  Index (PASI) score greater than or equal to 12,an Investigator Global Assessment 
modified 2011 (IGA) of at least 3, and who were candidates for phototherapy  or sy stemic therapy .
Trial 1 enrolled 738 subjects (245 randomized to secukinumab 300 mg, 245 to secukinumab 
150 mg, and 248 to placebo). Subjects received subcutaneous treatment at Weeks 0, 1, 2, 3,
and 4 followed b y dosing every  4 weeks. Subjects randomized to secukinumab received 300 
mg or 150 mg doses at Weeks 0, 1, 2, 3, and 4 followed by  [CONTACT_209768]  4 weeks. 
Subjects randomized to receive placebo that were non -responders at Week 12 were then 
crossed over to receive secukinumab (either 300 mg or 150 mg) at Weeks 12, 13, 14, 15, and 
[ADDRESS_390966] administration of study  treatment.
Trial 2 enrolled 13 06 subjects (327 randomized to secukinumab 300 mg, 327 to secukinumab 
150 mg, 326 to placebo and 323 to a biologic active control). Secukinumab and placebo data 
are described. Subjects received subcutaneous treatment at Weeks 0, 1, 2, 3, and 4 followed 
by [CONTACT_51034]  4 weeks. Subjects randomized to secukinumab received 300 mg or 150 mg 
doses at Weeks 0, 1, 2, 3, and 4 followed b y the same dose every 4 weeks. Subjects 
randomized to receive placebo that were non -
responders at Week 12 then crossed over to 
receive secukinumab (either 300 mg or 150 mg) at Weeks 12, 13, 14, 15, and [ADDRESS_390967] 
administration of study  treatment.
Trial 3 enrolled 177 subjects (59 randomized to secukinumab 300 mg, 59 to secukinumab 150 
mg, and 59 to placebo) and assessed safet y, tolerability , and usability  of secukinumab self -
administration via prefilled syringe for 12 weeks. Subjects received subcutaneous treatment at 
Weeks 0, 1, 2, 3, and 4, followed by  [CONTACT_209768]  4 weeks for up to 12 weeks total.
Trial 4 enrolled 182 subjects (60 randomized to secukinumab 300 mg, 61 to secukinumab 150 
mg, and 61 to placebo) and assessed safet y, tolerability , and usability  of secukinumab self -
administration via Sensoread y pen for [ADDRESS_390968] 75% (PASI 75) from baseline to Week 12 and treatment 
success (clear or almost clear) on the Investigator’s Global Assessment modified 2011 (IGA mod 
2011). Other evaluated outcomes included the proportio n of subjects who achieved a reduction in 
PASI  score of at least 90% (PASI  90) from baseline at Week 12, maintenance of efficacy  to 
Week 52, and improvements in itching, pain and scaling at Week 12 based on the Psoriasis 
Symptom Diary©.
The PASI  is a compo
site score that takes into consideration both the percentage of body  surface 
area affected and the nature and severit y of psoriatic changes within the affected regions 
(induration, erythema and scaling). The IGA mod 2011 is a 5 -category  scale including “0 = clear” 
“1 = almost clear”, “2 = mild”, “3 = moderate” or “4 = severe” indicating the physician’s overall 

[COMPANY_001] Confidential Page 25
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
assessment of the psoriasis severity  focusing on induration, erythema and scaling. Treatment 
success of “clear” or “almost clear” consisted of no signs of psoriasis or normal to pi[INVESTIGATOR_317577], no thickening of the plaque and none to minimal focal scaling.
The results of Trials 1 and 2 are presented in Table 3 -1.
Table 3
-1 Clinical outcomes at Week 12 in adults with plaque psoriasis in Trials 1 
and 2
Trial 1 Trial 2
Secukinumab
300 mg
(N=245)
n (% )Secukinumab
150 mg
(N=245)
n (% )Placebo
(N=248)
n (% )Secukinumab
300 mg
(N=327)
n (% )Secukinumab
150 mg
(N=327)
n (% )Placebo
(N=326)
n (% )
PASI 75 
response200 (82) 174 (71) 11 (4) 249 (76) 219 (67) 16 (5)
IGA of 
clear or 
almost clear160 (65) 125 (51) 6 (2) 202 (62) 167 (51) 9 (3)
The results of Trials 3 and 4 are presented in Table 3 -2.
Table 3
-2 Clinical outcomes at Week 12 in adults with plaque psoriasis in Trials 3 
and 4
Trial 3 Trial 4
Secukinumab
300 mg
(N=59)
n (% )Secukinumab
150 mg
(N=59)
n (% )Placebo
(N=59)
n (% )Secukinumab
300 mg
(N=60)
n (% )Secukinumab
150 mg
(N=61)
n (% )Placebo
(N=61)
n (% )
PASI 75 
response44 (75) 41 (69) 0 (0) 52 (87) 43 (70) 2 (3)
IGA of 
clear or 
almost clear40 (68) 31 (53) 0 (0) 44 (73) 32 (52) 0 (0)
Examination of age, gender, and race subgroups did not identify  differences in response to 
secukinumab among these subgroups. Based on post-hoc sub-group analy ses in subject s with 
moderate to severe psoriasis, subject s with lower body  weight and lower disease severity  may 
achieve an acceptable response with secukinumab 150 mg.
PASI  90 response at Week 12 w as achieved with secukinumab 300 mg and 150 mg compared to 
placebo in 59% (145/245) and 39% (95/245) versus 1% (3/248) of subjects, respectively  (Trial 1) 
and 54% (175/327) and 42% (137/327) versus 2% (5/326) of subjects, respectivel y (Trial 2). 
Similar re sults were seen in Trials 3 and 4.
With continued treatment over 52 weeks, subjects in Trial 1 who were PASI  75 responders at 
Week 12 maintained their responses in 81% (161/200) of the subjects treated with secukinumab 
300 mg and in 72% (126/174) of subjec ts treated with secukinumab [ADDRESS_390969] clear on the IGA at Week 12 also maintained their responses in 74% 

[COMPANY_001] Confidential Page 26
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
(119/160) of subjects treated with secukinumab 300 mg and in 59% (74/125) of subjects treated 
with secukinumab 150 mg. Similarly  in Trial 2, PASI  75 responders maintained their responses in 
84% (210/249) of subjects treated with secukinumab 300 mg and in 82% (180/219) of subjects 
treated with secukinumab [ADDRESS_390970] clear on the IGA 
also maintained their responses in 80% (161/202) of subjects treated with secukinumab 300 mg 
and in 68% (113/167) of subjects treated with secukinumab 150 mg.
Among the subjects who chose to participate (39%) in assessments of patient reported outcom es, 
improvements in signs and symptoms related to itching, pain, and scaling, at Week 12 compared 
to placebo (Trials 1 and 2) were observed using the Psoriasis Sy mptom Diary©.
Infections
Secukinumab may increase the risk of infections. In clinical trials, a higher rate of infections was 
observed in secukinumab -treated subjects compared to placebo -treated subjects. In placebo -
controlled clinical trials, higher rates of common infections such as nasophary ngitis (11.4% 
versus 8.6%), upper respi[INVESTIGATOR_2826] (2.5% versus 0.7%) and mucocutaneous infections 
with candida (1.2% versus 0.3%) were observed with secukinumab compared with placebo. The 
incidence of some types of infections appeared to be dose-dependent in clinical studies. Proper 
exclusion criteria will be applied in this study  to ensure subject safet y.
Pre-treatment evaluation of tuberculosis
Evaluate subject s for tuberculosis (TB) infection prior to initiating treatment with secukinumab . 
Do not administer secukinumab to subject s with active TB infection. Initiate treatment of latent 
TB prior to administering secukinumab . Consider anti-TB therapy  prior to initiation of 
secukinumab in subject s with a past history  of latent or active TB in whom an adequate course of 
treatment cannot be confirmed. Subject s receiving secukinumab should be monitored closely  for 
signs and s ymptoms of active TB during and after treatment.
Inflammatory  Bowel Disease
Caution should be used when prescribing secukinumab to patients with inflammatory  bowel 
disease. Exacerbations, in some cases serious, occurred in secukinumab treated patients during 
clinical trials in plaque psoriasis, psoriatic arthritis and anky losing 
spondylitis. In addition, new 
onset inflammatory  bowel disease cases occurred in clinical trials with secukinumab. In an 
exploratory  study in 59 patients with active Crohn’s disease, there were trends toward greater 
disease activity  and increased adverse events in the secukinumab group as compared to the 
placebo group. Patients who are treated with secukinumab should be monitored for signs and 
symptoms of inflammatory  bowel disease.
Hypersensitivity  reactions
Anaph ylaxis and cases of urticaria occurred in secukinumab -treated subject s in the clinical trials. 
If an anaph ylactic or other serio us allergic reaction occurs, administration of secukinumab should 
be discontinued immediately  and appropriate therapy  initiated.

[COMPANY_001] Confidential Page 27
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390971] a positive 
benefit/risk ratio for the treatment of moderate to severe psoriasis with secukinumab. It is 
therefore considered appropriate to initiate this study .It is unclear if there is an additional benefit 
for vascular inflamma tion in psoriasis subject s, and therefore, this study  is being conducted to 
evaluate this question.
The Investigator’s Brochure (IB) provides a more detailed review of the pre-clinical and clinical 
information on secukinumab.
[ADDRESS_390972] 18 years of age with 
moderate to severe chronic plaque psoriasis that requires sy stemic therapy  as defined by[CONTACT_317596] y controlled by [CONTACT_12523][INVESTIGATOR_12969] (including topi[INVESTIGATOR_11930] (TCS)), 
ultraviolet (UV) light, or sy stemic therapy .
The goal is to randomize a total of approximately  84 subjects in approximately  10 centers in the 
[LOCATION_002]. Assuming a 20% screen failure rate, [ADDRESS_390973] to fulfill all of the following criteria:

[COMPANY_001] Confidential Page 28
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
1.Provide wri tten, signed and da ted inform edconsent beforeany study-related activity i s 
performe d; where rel evant, a legal repres entative willalso sign the inform ed s t udyconsent
accord ingto local laws an d regu lations
2.Males and females 
≥[ADDRESS_390974] 6 months prior to randomization as 
determined b y subjec t interview of his/her medical history  and c onfirmation of diagnosis 
through ph ysical examination by  [CONTACT_737]
4. Moderate to severe pl aque psoriasis as definedatBaseline by:
≥10% Bod y Surface Area (BSA) involvement and
PASI  score of ≥12 and
IGA mod 2011 score of ≥3 (based on a scale of 0 – 4)
5.Candidate for s ystemic therapy , defined as having plaque psoriasis inadequately  controlled 
by:
topi[INVESTIGATOR_131525]/or
phototherap y and/or
previous sy stemic therapy
6.Physical examination and FDG -PET/CT scan without clinically  significant findings that 
would meaningfully  alter the risk -benefit profile of secukinumab in the Investigator’s opi[INVESTIGATOR_1649], 
and clinical laboratory  results within laboratory  reference ranges, or abnormal results that are 
deemed to be not clinically  significant b y the Investigator, in co nsultation with the Medical 
Monitor, and noted in the source documents
4.[ADDRESS_390975] s.
1. Forms of diagnosed psoriasis ot her than chr onic plaque psoriasis (e.g., e rythrodermic, 
generalized or localized pustular psoriasis, or new onset guttate psoriasi s)
2.Medication -induced or medication exacerbated psoriasis (e.g., newonset or cu rrent
exacer bation fro m beta-blo ckers, calcium c hanne l inhibitors or lithium)
3.Previous exposure to secukinumab or an y other biologic drug directl y targeting IL -17A or IL -
17RA receptors (e.g., ixekizumab, or brodalumab)
4. Diagnosis of other active ongoing skin diseases or skin infections (bacterial, fungal, or viral), 
or inflammatory  diseases other than psoriasis that may  interfere with the evaluation of 
psoriasis
5.Subject s not willing to limit UV light exposure (e.g., sunbathing and/or use of tanning 
devices) during the course of the stud y

[COMPANY_001] Confidential Page 29
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
6. O ngoing use of prohibited psoriasis tr eatments (e.g., topi[INVESTIGATOR_317578] c corticosteroid s,other 
topi[INVESTIGATOR_5910], sy stemic psoriasis treatments oral or biological, U
V therapy); washout 
periods detailed in the protocol must be followed (Table 5-2 )
7.Use of an y investigational drug within [ADDRESS_390976] s using cholesterol -
lowering medication (e.g., statins) and not on a stable dose for at 
least 90 day s prior to randomization and unable to remain on a stable dose for the duration of 
the study
9. Pr egnant or nursi ng ( l actating) women, where pregna n cy is d efine d ast he state of a femal e 
after concep tion and until the ter mi nation of gestation, confirmed bya positi ve hu man
chorionic gonadot r op in (hC G)l aboratory test
10.Women of c
hild- bear i ngpotential, defi ned as a ll women p hysiologicallycapable of bec oming
pregna n t, unless th ey are u sing eff ectivemethods of contr acep tion duri ngdosing of study
t
reatment andfor 16 weeks a fte r stoppi [INVESTIGATOR_317579] r eatment. E ffective contr aception methods in clude:
Total abstinence (when this is in line with the preferred and usual lifest yle of the subject . 
Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation methods) 
and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment.  I n case 
of oophorectom y alone, only when the reproductive status of the woman has been 
confirmed b y follow up hormone level assessment
Male sterilization (at least 6 m prior to screening); for female subjects on the study , the 
vasectomized male partner should be the sole partner for that su bject
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/ vaginal suppository
Use of oral, injected or implanted hormonal methods of contraception or other forms of 
hormonal contraception that have comparable efficacy  (failure rate <1%), for example 
hormone vaginal ring or transdermal hormone contraception
Placement of an intrauterine device (IUD) or intrauterine s ystem (IUS)
In case of use of oral contr aception, women sh ould have been st able on the same pil l fora 
minimum of 12 w eeks before taki ngstudy treatment.
NOTE
:Women are consider edpost-meno paus al and not of child-bear i ngpotential if the y have
had:
12 months of natu ral (sp ontaneous) ameno rrheawith anappropriate c lin ical p rofile (e.g., 
age app ropriat e,history of vasomotor sympto m s), or
Surgical bilateral oophorectomy (with or without hys ter ectom y)or tubal ligation a t l east 6
weeks ago. In case of oophorectomy alo ne,o nly when the rep roductive stat us of the
woman hasbeen confirmed by [CONTACT_317597] s he consider ednot 
o
f child-beari ngpotent ial

[COMPANY_001] Confidential Page 30
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390977] atincr eased risk (e.g., 
uncontrolled diabetes as evidenced b y hemoglobin A
1c ≥7%, m yo cardial infarction within 6 
months prior to screening, unstable ischemic heart disease, cerebrovascular accident )
12.Significant medical problems, including but not limited to the following: uncontrolled 
hypertension with measured s ystolic >180 mmHg and/or diastolic > 95 mmHg, congestive 
heart failure ([LOCATION_001] Heart Association [NYHA] status of class III or IV
13.Serum crea tinine level >2.0 mg/dL (>176.8 µmol/L) or fasting blood glucose ≥150 mg/dL or 
hemoglobin A1c ≥ 7%at screening
14.Tota
lwhite blood cell ( WBC) count < 2,500/µl, or throm bocytes < 100,000 /µl,or neu trophils
<1,500 /µl, or hemo globin <8.5 g/dL  at screening
15. His tory of lymphopro liferative diseas e or anyknown malignancy or history of malignan cy o f
any organ system within the past 5 y ea rs (except for skin Bo wen’s dis ea se, squamous cell 
carcinoma , basal cel l ca rcinoma, actinic keratoses that have been treated, carcinoma insituo f
thecervix, or non- invasive malignant colon po lypst h at have b een remov ed)
16.History  of an ongoing, chronic o r r ecurrent infectious diseas e,orevidenceo f tuberculosi s 
i
nfection asdefined by a p ositive or indeter mina teQuan tiFERONTB-Gold tes t (QFT) a t 
screeni ng. Subject s with a positi veQ F T test may participate in the study if a ful l t uberculosis
w
ork up ( acco rd ingto local p ractice/guidelines) completed within [ADDRESS_390978] 4 weeks p rior to rando mizationand the course of proph ylaxis is 
planned to be completed
17.Positive serology forhuman immunodeficiency  virus ( HIV), hepatitis B or C infection, or 
known history  ofother severe, recurrent or persistent infections
18.Any unde r
lying c on dition (incl uding, but notlimited to meta bolic, hematol ogic,renal,hepatic,
pulmonary,neurologi c,e n docrine, cardia c, infecti ous or gastrointestin al) whi ch,in theopi[INVESTIGATOR_317580], significantly imm unocompromises th e subject and/ orplaces th e subject at
unacceptable riskfor receiving a n immunom odulato rytherapy
19.
Active systemic in fections duri ngthe 2 weeks prior to rando miz ation (e xcep tion: common 
cold) or any infection t hatreoccurs on a re gularbasis
20.Plans for administration of live vaccines during the study  period or 6 weeks before 
randomization
21.Any medical or ps ychiatric condition which, in the Investigator’s opi[INVESTIGATOR_1649], would preclude the 
subject from adhering to the protocol or completing the stud y per protocol
22.
Histo ryor ev idence o f ongoing substance abuse withi n 12 months prior to screening, or not 
willing to limit alcohol use to ≤14 drinks per week within 4 weeks prior to Baseline and 
throughout the duration of the study
23.History  of hypersensitivity  to constituents of the study  treatment and/or subject s who are 
allergic to rubber or latex (the needle cap of the single -use prefilled sy ringe for secukinumab 

[COMPANY_001] Confidential Page 31
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
and placebo may  contain natural rubber latex which may  cause allergic reactions in latex 
sensitive individuals
)
24.Subject s who a re no table and/or not wi lling to self -administer secukinum ab i njecti ons or who 
have no trai ned ca r egiver av ailable toadministe r these injecti ons
5 Treatment
5.1 Protocol requested treatment
5.1.1 Study treatment
The following stud y treatments will be used:
Study drug
oSecukinumab 150 mg; 1 ml liquid formulation in a single-use prefilled s yringe (PFS )
Control drug
oPlacebo to secukinumab 150 mg; 1 ml liquid formulation ina single -use prefilled 
syringe (PFS)
Study drug: secukinumab 300 mg
Secukinumab for subcutaneous (s.c.) injection is provided in a prefilled syringe (PFS) containing 
150 mg secukinumab. Each secukinumab 300 mg dose is given as two s.c. injections of 150 mg.
Control drug: placebo
Placebo to s ecukinumab 150 mg f or s.c. in jection is provid edin a matchi ngprefilled syri nge (PFS).
EachPFS contains a mixtur e of inactive excipi[INVESTIGATOR_840], matching the composition of the se cuk inumab
[ADDRESS_390979] acebo prefill edsyringes wi llbe supp liedby
[CONTACT_5343].
All study treatments w illbe labeled appropriately.
5.1.2 Additional study treatment
No additional treatment bey ond study treatment is requested for this trial.
5.2 Treatment 
groups
At Visit 2/Baseline , eligible subject s will be randomized to one of the following two treatment 
groups in a ratio of 1:1, with approximately  [ADDRESS_390980] s per group :
1.Secukinumab group :  Subject s (or trained caregivers) will self- administer (or administer to 
the subject ) a dose of secukinumab 300 mg s.c. (two injections of the 150 mg prefilled 

[COMPANY_001] Confidential Page 32
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
syringes) once weekl y for five weeks ( at Randomization, Weeks 1, 2, 3, and 4), followed b y 
dosing every  four weeks, starting at Week 8through Week 48. In order to maintain the 
blinding during the Double -blind I nduction Period, placebo s.c. doses (two injections of the 
placebo to 150 mg prefilled sy ringe) will be self -administered by  [CONTACT_423] s (or trained 
caregivers) at Weeks 13, 14 and 15.
2.Placebo group :  Subject s (or trained caregivers) will self-administer (or administer to the 
subject ) a dose of placebo s.c. (two injections of the placebo prefilled s yringes) once weekl y 
for five weeks (at Randomization, Weeks 1, 2, 3, and 4), followed b y a dose after four weeks 
at Week 8. 
Beginning at Week 12, all subject s in the placebo group will be switched to treatment with 
secukinumab [ADDRESS_390981] s will receive a dose of secukinumab 300 mg s.c. once 
weekl y for five weeks (at Weeks 12, 13, 14, 15, and 16) followed by  [CONTACT_317598], 
starting at Week [ADDRESS_390982] s who enter the Double- blind Induction Period will self-administer the Week 12 dose 
following the completion of all assessments scheduled to be performed at Visit 8/W eek 12 ( Table 
6-1).
The treatment groups and dosing frequency  are also described in Table 5 -
1below.
Table 5-
1 Overview of study  treatment
Treatment group DBTreatment Period 
(Rand – Wk 12 pre -dose)DBInduction Period
(Wk 12 –Wk 15 )OLTreatment Period
(Wk 16 –Wk 52)
Secukinumab 300 mg 
2x s.c. secukinumab 150 
mg injection at Rand, W ks 
1, 2, 3, 4 and 82x s.c. secukinumab 150 
mg injection at  Wk 12
2x s.c. secukinumab 150 
mg PBO injection at Wks 
13, 14 and 152x s.c. secukinumab 
150 mg injection at  
Wks 16 -48
Placebo (PBO)
2x s.c. secukinumab 150 
mg PBO injection at Rand, 
Wks 1, 2, 3, 4 and 82x s.c. secukinumab 150 
mg injection at Wks 12, 
13, 14, and 152x s.c. secukinumab 
150 mg injection at  
Wks 16 –48
DB = Double -blind; OL = Open -label; Rand = Randomization; Wk = Week
5.3 Treatment Assignment, randomization
At Visit 2 /Baseline , all eligible subject s will be randomized via Interactive Response Technology  
(IRT) to one of two treatment groups . The Investigator or his/her delegate will contact [CONTACT_317599]/exclusion criteria. The IRT will assign a 
randomization number to the subject , which will be used to link the subject to a treatment group
and will specify  a unique medication number for the first box of study treatment to be dispe nsed 
to the subject . The randomization number will not be communicated to the caller.

[COMPANY_001] Confidential Page 33
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390983] s and Investigators/site staff. A 
subject randomization list will be produced by [CONTACT_6609] a validated system that 
automates the random assignment of subject numbers to randomization numbers. These 
randomization numbers are linked to the two different treatment groups , which in turn are linked 
to medication numbers. A separate medication list will be produced by  [CONTACT_317600] (DSM) using a validated system that automates the 
random assignment of medication numbers to boxes containing the study  treatments(s).
The randomization scheme for subject s will be reviewed and approved by a  m ember of the 
[COMPANY_001] Biostatistics Group.
5.[ADDRESS_390984] s,Investig a tors /site staff,persons performing asses sments, and [COMPANY_001] study  personnel
willremainblinded t o individual treatment assign ment from thetime ofrando mization until the 
final database lock at Week 52 ,using thefollowing methods:
1.Randomization data willbekept strictlyconfidential untilthetime of unblinding, andwill not
be accessible by[CONTACT_317601]:
specific vendors whose roleintrialcondu ctrequires their unblinding (e.g., IRT)
Drug Supply  Management (DSM );
2.The identity  of secukinu mabandplacebo prefilled sy ringes (PFS) will be concealed by[CONTACT_317602], labeling, schedule ofadministration, andappearance.
Atthe Week [ADDRESS_390985] 
completed theWeek 12visit. At that time, only the statistician and programmer (s)from the 
designated CRO will be unblinded in order to perform the analysis.Results from the analyses of 
all data through Week 12, including the data for the primary  efficacy  variable, will be reported. 
For publication purposes, summary  results from the Week [ADDRESS_390986] emergencies (see Section 5.5.12), at the time of 
the primary  analysis (Week 12) for designated CRO personnel only, and at the conclusion of the 
study .
A
fu
ll analysi s of all data co llecteduptoWeek52 wi llbe performed when all subject s have 
completed the W eek52 visit.

[COMPANY_001] Confidential Page 34
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390987] is assigned the next sequential number by 
[CONTACT_093]. The Investigator or his/her staff will contact [CONTACT_317603]. The site should select the 
eCRF book with a matching Subject Number from the EDC sy stem to enter data. 
If asubject fails to be randomized for any reason, the IRT must be notified that the subject was 
not randomized. The reason for not being randomize d will be entered on the Screening Phase
Disposition eCRF.
5.5.2 Dispensing the study treatment
Each study  site will be supplied by [CONTACT_268285]. The secukinumab and placebo treatment packaging has a 2-
part label. A unique medication number is printed on each part of this label.
Investigat or/qualified site staff will identify thestudy treatm entbox(es)todispense tothe 
subject by[CONTACT_317604] m edication number(s). Immediately 
before dispensing thestudy  treatment tothesubject ,sitestaffwill detach theouter partofthe
label from the box and affix it to theDrug Label Form source document forthatsubject .
IRT will assign secukinum abor placebo ateach visit from Randomization toWeek48. All 
boxes of investigational treatment assigned by [CONTACT_317605]/databased in the IRT 
system.
5.5.[ADDRESS_390988] their monitor 
for guidance on the reporting and returns process.
Theprefilled syringes(150 mgsecukinumab or placebo) sealed intheir outer boxmust be st ored 
in a l ocked refrigerator bet ween 2° to 8°C (36° to 46°F)andmust be carefully contr olledin
accordance with reg ulations governi n g investigational medici nal products andlocal regula tions. 

[COMPANY_001] Confidential Page 35
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Study treatment sh ould not b e frozen . All temperature excursions (either below or above the 
required, specified temperature range) must be reported to [COMPANY_001] for review and assessment of 
impact on the study  treatment. In the event of a temperature excursion, site staff should contact 
[CONTACT_268287].
Medication labels will be in English and will comply  with US legal requirements. They  will 
include storage conditions for the study  treatment but no information about the subject except for 
the medication number .
The Investigator must maintain an accurate record of the shipment and dispensing of study  
treatment in a drug accountability  log. Monitoring of drug accountability will be performed by 
[CONTACT_314920] y, and at the completion of the trial. Subject s will be asked 
to return all used/unused study  treatment and packaging to the study  site.
At the conclusion of the study , and as appropriate during the course of the study , the Investigator 
will return all used and unused study treatment, packagin g, drug labels, and a copy of the 
completed drug accountability  log to the [COMPANY_001] or responsible CRO monitor, or to the [COMPANY_001] 
or responsible CRO address provided in the investigator folder at each site.
[IP_ADDRESS] Handling of other study  treatment
Not applicable .
5.5.4 Instructions for prescribing and taking study treatment
Throughout the duration of the study , alldoses of study  treatment(secukinumab 300 mgand
placebo) will beself-administered subcutaneously (s.c.) by [CONTACT_423] (or trained caregiver)
after all study  assessm ents foreach visit have been completed. The prefilled syringes will be
provide d by [CONTACT_317606] ,who willthen self-inj ect thestudy treatment . Site staff 
should remove the assigned study  treatment from the refrigerator and allow the syringes to reach 
room temperature in their unopened box (approximately  15-30 minutes) before self-injection by 
[CONTACT_1560] .
Allself-injections during the Double -blind Treatment Period will take place atthestud y
site; during the Double- blind Induction and Open -label Treatment periods, self-injections will 
occur both at the study  site and at home. Instructions onthes elf-administ ration ofthestudy 
treatment and disposal of used prefilled syringes aredetailed inthesecukinumab Instructions
F
or Us e (IFU) document and will be provi dedtoeachsubject .
Atthebeginning ofthestudy ,theInvestigat or/qualified sitestaff will deter mineifself-
adm
inistration isappropria te for thesubject ,e.g., manual dexter ity,ability tofollow the IFU. If
asubject requires acaregiver toadminister study treatment, the caregiver will betrained by  [CONTACT_941] 
I
nvestiga tor /qualif ied site staff . Ifa caregiver isnotavaila bleataparticular visit o rthesubject is
havingproble ms with self-administration, theInvestigator/qualified sitestaff mayadmi nister the
study treatm
enttothe subject .

[COMPANY_001] Confidential Page 36
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390989] sshould self-administerthestudy treatment toone ofthefollowing body
regions, changing theinjection site routinel y:the front of the thigh s,the lower stomach area 
(abdomen) but not the area two inches around the navel . In cases where a car egiver will 
administer thestudy treatment,theupper outer arms may also be used a s aninjection site.
The first study  treatment self-administration will occur atVisit 2/Baseline after 
inclusion/exclusion criteria have been confir m
ed,allscheduled study  assess ments have been
perfor m
ed, and the clinical report from the Visit 2/Baseline FDG -PET/CT scan has been received 
and reviewed with no clinically  important findings that would preclude the subject from 
continuing in the study . The first dose of study  treatment willtake place under t
hesupervision of
the Investigat or/qualified site staff .The subject will be in structed on the use ofthe 
secukinu
mab/placebo prefilled syringe viareview ofthe secukinum abIFU. At subsequent
visits, the Investigator/qualified site staff will observe the self-adm inistration of
secukinum ab/placebo atthesite.
Administration
Each dose of study  treatment (two prefilled syringes of secukinu mab 150mg or placebo) will be
packed inanindivid ualbox. For further details about study treatmentstorage and handling,
please
refer tothesecukinum ab IFUdistributed astraini ngmaterial forthestudy .
During the Double -blind Treatment P eriod (from Randomization through Week 8),subject s
willself-inject atotal of 12 secukinum ab or placebo injections (two injectionsper visit). 
During the Double -blind Induction Period (from W eek12through Week 15),subject swill
self-inject a total of 8 injections (two injections at Week 12, and two injections at home at Weeks 
13, 14 and 15).
During the Open -label Treatment Period (from W eek16through Week 52),subject swillself -
inject a total of 18 injections (two injections pervisit at Weeks 16, 24, 32, 40, and 48 and two 
injections at home at Weeks 20, 28, 36, and 44).
Date andtime of secukinum abor pl acebo self-admi nistrations during the study mustberecorded
ontheDosage Admi nistration Record eCRF.
5.5.5 Permitted dose adjustments and interruptions of study  treatment
Study treatment dose adjustments and/or interruptions are not permitted.
5.5.6 Rescue medication
Rescue medication is not permitted in this study .

[COMPANY_001] Confidential Page 37
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
5.5.7 Concomitant treatment
All treatments ad ministered during the six months prior to the Randomization visit (including any  
treatments started during the screening period) for any reason NOT including psoriasis will be 
entered on the Prior and Concomitant Medications eCRF or the Surgical and Medica l Procedures 
eCRF with the reason for administration.
Psoriasis tr eatments us edfrom the t ime the subject started to treat his/her psoriasis will b e 
repor
ted on the Prior Psoriasis Therapy eCR F. All top ical tr eatments, syste mic treatment s, and 
phototherapi [INVESTIGATOR_317581] p soriasis ad minister edprior tor ando miz ation wi llberecorded (Section 
6.2.2).
The Investigator 
should instructthesubject tonotify site staff aboutanynew t r eatments he/she
takes after thestart ofthestudy treatment.All medi cations andsignificant non-drug therapi[INVESTIGATOR_014]
(including physical therapyandblood transfusions) administered after thesubject starts study
treatmentmust berecorded on the Prior and Concomitant Medications eCRF orthe Surgical and 
Medical Procedures eCRF asappropriate. Information recorded will include indication for use, 
dosage, and dates of administration.
5.5.8 Prohibited Treatment
Use of a nytreatment s displayed in Table 5-2t hat could conf ound the effic acy of the study  drug
arenotallowed during the study for any indicatio n; wash-out periods for these treatments ar e 
provid ed in Table 5-2. If the use of these treatments is r equ ired, then the subject must notbe 
rando mizedinto the study.
T
he I nvestigator/qualified site staff must instruct the subject t o no tify them about anynew 
treatments he/she takes after the start of the st udy t reatment. All prohibited medi catio ns and 
significant non-dr ugt herapi[INVESTIGATOR_317582] b e 
listed on the Prior and Concomitant Medi cations eCRF and the Surgical and Medical Procedures
eCRF as appropriate ,or the Concomitant Medi cations- Topi[INVESTIGATOR_317583] r r ando mization.
If a prohibited treatment li sted in Table 5-[ADDRESS_390990] 
discontin ue use of the prohibited treatment if he/she wishes to continue in the study. If, in the 
Investigator’s clinical judgment, t
hesubject ’s use of a prohib ited tr eatment presents an 
undue safet y r isk for the subject , the subject mustbe discontinued from study treatment as per
Section 5.5.9. 
I
f asubject receives a live virus v ac cination duri ngthe stu dy, the subject must discontinu e s tudy
t
reatment and complete an end -of-treatment visit (either Visit 8/Week 12 EOT1 or Visit 
14/Week 52 EOT2 ).
Any other protoco l deviation th atr esults in a signifi cant risk tothesubject ’s safety wi llbe 
recorded.

[COMPANY_001] Confidential Page 38
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390991] swill beadvised tolimit exposur e tou ltr aviolet ( UV) light (including sunbathing and/or
use of UVt anning d evices) during the st udyt o avoid p ossib le effects on psoriasis.
Table 5-2 Prohibited treatment
Prior Therapy (Before Visit 2/ Baseline )
Prohibit edTreatm ents†,‡Washout Period
(before Randomization)
Secukinumab No prior use allowed
Any biol ogic dru g directly tar getin g IL-17 or the IL-17 rec eptor
(other than secuki numab)No prior use allowed
Alefac ept, briakinum ab, efalizumab , ustekinumab 6 months
Biologica l immunom odulating agen ts other than above
(e.g., adalimum ab, inf liximab, etanercept)3 months
Cholesterol -lowering medication (e.g., statins)Dose must be stable for ≥90 days 
prior to randomization and remain 
stable for the duration of the study
Other systemic i mmunom odulating tr eatm ents§ [e.g., MTX,
cyclosporine A,corticosteroids (or al, i.v., intramuscula r, s.c.,
intra-articula r,transdermal)§, cyclopho sphamide]4 weeks
Other systemic psoriasis tr eatm ents (e.g.,retinoid, fumarates) 4 weeks
Photo chemot herapy (e.g., PU VA) 4 weeks
Phototherapy (e.g., UVA, UV B) 2 weeks
Medicated psoriasis shampoo (including OTC) [ADDRESS_390992] si gnsand symptoms o f 
psoriasis (e.g., vitami n D anal ogue s,pi[INVESTIGATOR_031], ret inoids, 
salicylvase line, salicylic acid, lactic acid, ta crolimus, tar, ur ea,
α-hydroxy or fruit acid s)2 weeks
Topi[INVESTIGATOR_24946] (TCS) any potency on areas of 
psoriasis2 weeks
Live virus vaccines 6 weeks
Any investigational treatment or participation in any 
interventional trial4 weeks or 5 half -lives
(whichever is longer)
Any other treatment known to worsen psoriasis (e.g., beta -
blockers, calcium channel blockers)Stable dose for at least 4 weeks prior 
to randomization
Concomitant Th erapy with TCS ( after Visit 2/ Baseline )
Topi[INVESTIGATOR_24946] (TCS) Concomitant Use
TCS on areas of psoriasis (including scalp) Hydrocortisone 2.5% cream is 
allowed on face and intertriginous 
areas, and medicated OTC shampoos 
areallowed for the scalp 
TCS m ild to m oderate potencyused for up to 7 consecutive 
days per event for an indication other than psoriasis and on 
areas notaffected by [CONTACT_268294] 39
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
†If the prohi bited treatment was use d durin g the study for any indicati on, th e subject must disc ontinue u se of the 
prohi bited treatm ent ifhe/she wishes t o continue in the study.
‡
In case ofundu e safety risk for th e subject as determined by [CONTACT_737] , the subject should discontinue 
study tr eatm ent.If the subject receives a live virus vacci nation duri ng the study, the subject must disc ontinue 
study trea tment.
§
Inhaled CS wit h only a t opi[INVESTIGATOR_2855] e ffect(e.g., t o treat asthma) a re not c onsidered “system ic immunom odulating
treatm ents” and aretherefo re accept able a s co-m edicati on.
5.5.[ADDRESS_390993] s may voluntaril y discontinue study  treatment for any reason at any time. They may be 
conside redwithdrawn ifthey state anintention towithdraw , fail to re turn for vis its, or beco me 
losttofollow -
upforanyother reason. Subjects who prematurel y withdraw from the study will not 
be replaced.
If discontinuation o ccur s for any reason during the study , the Investiga tor/qua lified sit e staff
must m ake ev ery effort to d etermine the pr imary r eason for a subject ’s discontinu ation from the
study. This information will then be r eco rdedon theEnd of Treatment eCRFfor either the 
Double -blind Treatment Period (Visit 8/Week 12 EOT1), orthe Double -blind Induction and 
Open -label Tr eatment Periods (Visit 14 /Week 52 E OT2) as appropriate .
Study  treatment must be discontinued and the subject withdrawn from the study  if the 
Investigator on balance believes that continuation would be detrimental to the subject ’s well-
being. Study  treatment must be discontinued under the following circumstances:
Emergence of the following AEs: AEs that in the judgment of the Investigator/qualifi ed 
s
ite staff, taking into account the subject ’ s overall status, prevent the subject f rom 
continuing study treatment (fo r e xample, s epsis or serious in fection );
Any laboratory abnormalities that in the judgment of the Investiga tor /qualif ied site staff, 
taking into consideration the subject ’ s overall status, prevents the subject f rom continuin g 
studytreatmen t;
Pregnancy (see Section 6.5.6 andSection 7.3);
Ongoing use of any prohibited treatment, use of a prohibited treatment that results in an 
undue safet y r isk for the subject as per the Investigator’s clinical judgment, or receipt of a 
live virus vaccine during the study  (asdetailed in Section 5.5.8) ;
Emergency  unblinding;
Any other protocol deviation that results in a significant risk to the subject ’s safety  or 
significantl y affects the validity  of the stud y assessments.
Subject s who discontinue study  treatment should undergo an end of study  visit and then be 
discontinued from the trial.
Double -blind Treatment Period: For subjects who discontinue study  
treatment prematurely  
before the end of the Double- blind Treatment Period, the Visit 8/Week 12 EOT1 assessments 
should be performed. NOTE : Consultation with the Medical Monitor is required to 

[COMPANY_001] Confidential Page 40
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
determine if the FDG -PET/CT scan assessment should be performed during the 
discontinuation visit.
Double -blind Induction and Open -label Treatment Periods: For subjects who 
discontinue study  treatment prematurely  before the end of the Double -blind Induction or 
Open -label Treatment Periods, Visit 14/Week 52 EOT2 visit should be performed. NOTE : 
Consultation with the Medical Monitor is required to determine if the FDG -PET/CT 
scan assessment should be performed during the discontinuation visit.
Study  treatment must be discontinued after emergency  unblinding.
The appropriate personnel from the site and [COMPANY_001] will assess whether study  treatment should 
be discontinued for any subject whose treatment code has been broken inadvertentl y for any 
reason.
Scheduling of the end of treatment discontinuation visit
At the t ime of the end of studydiscontinuation visit, IF it has been approx im ately [ADDRESS_390994] udy treatmen t,THEN the a ssessments for Visit 8/Week 12 EOT1 (for early
discontinuation during the Double -blind Treatment Period ) orfor Visit 14/Week52 EOT2
(forearly discontinuation during Double -blind Induction orOpen -label Treatment Periods )
s
hould be co mpleted.
IF it has not b een approximately [ADDRESS_390995]
dose for thei r V isit8/Week12 (fo r early discontinuation du ring the Double -blind Treatment 
Period ) or Visit 14/W eek52 (forearly discontinuation during the Double -blind Induction or
Open -label Treatment Periods )a
ssessments.
The Investigator/site staff must also contact [CONTACT_37284] ’s discontinuation from 
the study .
5.5.[ADDRESS_390996] make every effort (e.g., telephone, email, 
letter) to determine the primary  reason for this decision and record this information. Study  
treatment must be discontinued and no further assessments conducted. All biological material that 
has not been analyzed at the time of withdrawal m ust not be used. Further attempts to contact [CONTACT_317607] y findings require communication or follow -up.

[COMPANY_001] Confidential Page 41
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_390997] s whose status is unclear because they fail to appear for study  visits without stating an 
intention to withdraw, the Investigator should show "due diligence" by [CONTACT_237187] , 
family  or family  physician as agreed in the informed consent and by [CONTACT_317608] , e.g., dates of telephone c alls, registered letters, etc. 
5.5.[ADDRESS_390998] , he/she mus t provide the request ed
subject identifyi ngi n formation and con firm the ne cessit y to br eakthe treatment code for the
subject .
The Investiga tor w ill then r eceive details of the study treatment for the specified subject
and a fax or emai l confirming this information. Th e s ystem will automatica lly inform [COMPANY_001]
and CRO study  personnel that t he code has been broken.
It is the Investigator’s responsibility  to ensure that there is a procedure in place to allow access to 
the IRT in case of emergency .
Study  treatment must be discontinued in the event of an emergency  unblinding.
5.5.[ADDRESS_390999] ’s individual study  participation is completed once Visit 14/Week [ADDRESS_391000] refer them for appropriate ongoing care.

[COMPANY_001] Confidential Page 42
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_391001] (as 
described in Section 5.5.9). The Investigator may be informed of additional procedures to be 
followed in order to ensure that adequate consideration is given to the protection of the subject ’s 
interests. The Investigator will be responsible for informing the Institutional Review 
Board/Inde pendent Ethics Committee (I RBs/IECs) of the earl y termination of the trial.
6 Visit schedule and assessments
Table 6-1lists all of the assessments and indicates with an “X” when the assessments are to be 
performed.
Subject s
should be seen for all visits on the designat edday or asc lose as p ossib letothe 
origina l planned visit schedule (rec ommended visit windo wsa re in Table 6-1. Every effo rt 
s
hould be made to res pect the time frame for the Visit 8/ Week12 visit.
At a minimum, subject s will be contact[CONTACT_317609] [ADDRESS_391002] should be recorded in the source documentation.
Visit windows
A“visit window” willbe allowed duringthestudyasfollows:
Screening Period
o+2 day s(for a total of up to 30 day s)
Double- blind Treatment Period
o± 2 day s for Visits 3-8
Open -label Treatment Period
o± 7days for Visits 9-14
Rescreening
Rescreening may be allowed under certain conditions. Requests from the Investigator/site staff 
to rescree n subject s will be handled on a case-by-case basis with Medical Monitor approval 
required before proceeding with the rescreening. Rescreening cannot be done if a subject was 
previously  randomized into the study .
Ifasubject rescr eens for the study, the subject must sign a new ICF and be issued a n ew
subject number. The date of the new informed consent signature [CONTACT_317635]. Informed consen t f or a rescr eenedsubject must be obtain edprior tope rfor ming
study -related assessmen tsor co llecting any data fo r theScreening Visit. For rescr eening, all

[COMPANY_001] Confidential Page 43
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_391003] be performed asper protocol, ex ce pt for the tuberculosis (TB)work
up, if app licable, if p erformed not more tha n [ADDRESS_391004] s may be seen at any time foran unscheduled visit, e.g., if they experience deterioration
ofpsoria sisorAEs thatintheopi[INVESTIGATOR_317584]/qualified sitestaffneed intervention
orrepeat laboratory testing. The assess ment(s) perform ed atan unscheduled visit must include 
at minimum: an assessment of concomitant medication and procedures/significant non-
drug therapi[INVESTIGATOR_014], vital signs, and an AE/SAE assessment. Any  additional assessments 
performed areattheInvestigator/qualified sitestaff’s discretion. During an unscheduled visit,
study treatmentwillnot be admi nistered.

[COMPANY_001] Confidential Page 44
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Table 6-1 Assessment schedule
Period SCR Double -blind Treatment Period Double -blind 
Induction 
PeriodOpen -label Treatment Period
Unscheduled VisitDVisit 1 2 3 4 5 6 7 8 / 
EOT1
A,B9 10 11 12 13 14/ 
EOT2
C
Week -4 to 
BLEBL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52
Visit window (Days) ±2 ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 ±7
Assessment
Obtain informed consent X
Demographics X
Inclusion/exclusion criteriaFX X
Smoking and alcohol history X
Psoriasis histor y / Prior
psoriasis therap y / Psoriatic 
arthritis histor yX
Cardiovascular medical 
historyX
Cardiovascular disease 
family historyX
Medical histor y / Current 
medical conditionsX
Prior and concomitant 
medications / Surgical and 
medical proceduresX X X X X X X X X X X X X X X
Physical examinationFX X X X X Xd
Height X

[COMPANY_001] Confidential Page 45
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Period SCR Double -blind Treatment Period Double -blind 
Induction 
PeriodOpen -label Treatment Period
Unscheduled VisitDVisit 1 2 3 4 5 6 7 8 / 
EOT1
A,B9 10 11 12 13 14/ 
EOT2
C
Week -4 to 
BLEBL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52
Visit window (Days) ±2 ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 ±7
Assessment
Weight X X X X X X X X X X X Xd
Vital signs X X X X X X X X X X X X
Lab analysis: Safety panel 
(chemistry , hematology)G X X X X Xd
Fasting labs: plasma 
glucoseX
Viral s erology lab analy sis: 
HIV, Hepatitis B and CG X Xd
QuantiFERON®TB-Gold 
In-Tube testG,H X Xd
Serum pregnanc y testG,IX Xd
Urine pregnancy test 
(local)J X X X Xd
FDG -PET CTKXLXMX
Blood sample for cardio -
metabolic biomarkersG X* X X X* X X X*
PASI X X X X X X X X X X X Xd
IGAmod 2011 X X X X X X X X X X X Xd
Alcohol use assessment X X X X X X X X X X X X Xd
DLQI X X X X X X X

[COMPANY_001] Confidential Page 46
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Period SCR Double -blind Treatment Period Double -blind 
Induction 
PeriodOpen -label Treatment Period
Unscheduled VisitDVisit 1 2 3 4 5 6 7 8 / 
EOT1
A,B9 10 11 12 13 14/ 
EOT2
C
Week -4 to 
BLEBL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52
Visit window (Days) ±2 ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 ±7
Assessment
AE/SAE assessment NX X X X X X X X X X X X X X X
Randomization via IRT X
Subject self -administration 
of study treatment at siteX X X X X X X X X X X X
Dispense study treatment to 
subject for at -home dosingX X X X X
Subject self -administration 
of study treatment at home 
and completion of Self -
Administration LogOX X X X X X X
At-home Dosing Phone 
ReminderF,P X X X X X
Check Self -Administration 
Log and returned 
used/unused study 
treatment and packagingF,QX X X X X Xd
AE=adverse event; BL = Baseline; DLQI=Dermatology Life Quality Index; EOT1=End of Treatment 1; EOT2=End of Treatment 2; FDG -PET CT=18 -
fluorodeoxyglucose positron emission tomography with computer assisted tomography; HIV=human immunodeficienc y virus; IGA=Inve stigator’s Global 
Assessment; IRT=Interactive Response Technology; PASI=Pso riasis Area and Severity Index; SAE=Serious Adverse Event; SCR=Screening; 
TB=tuberculosis
* At Visits 2, 8, and 14, s ubjects are required to be fasting for a minimum of 8 hours prior to the blood sample collection for cardiometabolic biomarke rs 

[COMPANY_001] Confidential Page 47
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Period SCR Double -blind Treatment Period Double -blind 
Induction 
PeriodOpen -label Treatment Period
Unscheduled VisitDVisit 1 2 3 4 5 6 7 8 / 
EOT1
A,B9 10 11 12 13 14/ 
EOT2
C
Week -4 to 
BLEBL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52
Visit window (Days) ±2 ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 ±7
Assessment
ASubjects will complete all Visit 8 /Week 12assessments prior to administration of study treatment 
BVisit 8 /Week 12assessments must be performed for subjects who discontinue treatment during the Double -blind Treatment Period . Consultation with 
the Medical Monitor is required to determine if th e FDG -PET/CT scan assessment should be performed during the discontinuation visit.
CVisit 1 4/Week 52assessments must be performed for subjects who discontinue treatment prematurely during the Double -blind Induction or the Open -
label Treatment Periods . Consultation with the Medical Monitor is required to determine if the FDG -PET/CT scan assessment should be performed during the 
discontinuation visit.
DUnscheduled visit – concomitant medications, vital signs, and AE/SAE assessment are required for an unscheduled visit; all other assessments are 
performed at the discretion of the Investigator
EVisits [ADDRESS_391005] not be performed on the same day
FThese assessments are supported by [CONTACT_109036]. Data relating to inclusion/exclusion criteria are ca ptured in the 
corresponding eCRF.
GSamples will be shipped to a central laborator y for analy sis
HA repeat QuantiFERON®TB-Gold In- Tube test is recommended if the result of the first QuantiFERON®TB-Gold In -Tube test is “indeterminate”. The 
subject must be referred for a follow -up tuberculosis workup (as per local guidelines) if either the first or the repeat test is “positive” or i f the results of 
both tests are “indeterminate”. If the first test is indeterminate, the Investigator may decide not to repeat the test and to proceed directly to the workup, 
though this is not recommended. The subject will not be eligible for randomizatio n if “active tuberculosis is present “or if “latent tuberculosis is present 
and is untreated as per local guidelines.
IA serum pregnanc y test is not required for a woman who is sterile or who is post -menopausal.
JA urine pregnanc y test is not required fo r a woman who is sterile or who is post -menopausal. In the event of a positive urine pregnancy test, study 
treatment must be withheld and a serum pregnanc y test performed at the same visit.
KThe FDG -PET/CT scan will be performed at each site’s local imaging center. A clinical reading scan report will be provided to the site within 24 hours of 
the scan by [CONTACT_317610] .

[COMPANY_001] Confidential Page 48
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Period SCR Double -blind Treatment Period Double -blind 
Induction 
PeriodOpen -label Treatment Period
Unscheduled VisitDVisit 1 2 3 4 5 6 7 8 / 
EOT1
A,B9 10 11 12 13 14/ 
EOT2
C
Week -4 to 
BLEBL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52
Visit window (Days) ±2 ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 ±7
Assessment
LThe Visit 2/Baseline FDG -PET/CT scan report mu st have been reviewed with no clinically significant findings prior to randomization and administration 
ofthe initial dose of study treatment (see Section [IP_ADDRESS] for additional information) . Randomization must occur 7 day s or less from date of FDG -PET/CT 
scan.
MThe Visit 8/W eek 12 FDG -PET/CT must have been re viewed with no clinically significant findings prior to the administration of the Visit 8/ Week 12 
dose (see Section [IP_ADDRESS] for additional information) . 
Subject s must administer their Week 12 dose 7 days or less from the date of their W eek 12 FDG -
PET/CT scan. 
NAE/SAE assessment includes injection site reactions 
OSubjects will self -administer study treatment at home at these time points and will record each dose administered at home in their Self -Administration 
Dosing Log
PSite staff to contact [CONTACT_317611] -home dosin g and completion of Self -Administration Log
QThe at -home administrations of study treatment will be recorded by [CONTACT_317612] -Administration Log which must be returned to the site at the 
next visit along with the used/unused study treatment and the outer boxes for a compliance check.

[COMPANY_001] Confidential Page 49
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_391006] be notified about the 
discontinuation, and theprimary  reason forthe screen failure should beentered in the 
Screening Phase Disposition eCRF.
The Scre eningVisit Date, Demogr aphy,InformedConsent, Inclusion/Exclusion Cr it eria, 
Subject Rescreening , and the Screening Phase Disposition eCRFs mustbecompleted. T he
Adverse E
venteCRFandapaper SAE form must becompleted foranyserious adverseevent
(SAE) that occursduringthe screeni ng period. A dverse events th ata re not SAEs will be
followed by[CONTACT_11856] a nd co llected only in the source data. The W ithdra wal of
Informed C onsent eCRF must be completed i f c onsent waswithd rawn du ring the Screeni ng
period before the subject wasrando mized.
6.[ADDRESS_391007] demographics/other baseline characteristics
All baseline assessments should be performed prior to the first study  treatment administration.
6.2.[ADDRESS_391008] sinclude: date ofbirth, subject initials, 
sex, race, ethnicity a ndchild-bearing potential (forfema lesonly).
6.2.2 Psoriasis history  / Prior psoriasis therapi[INVESTIGATOR_317585]. The information to be co llec tedand 
enter edin the eCRF includes th e f ollow ing:
date of first diagnosis of pl aque psoriasis ( bya physician );
previ ous psoriasis treatments (including pr evious use of systemic therapi[INVESTIGATOR_014], aswell as
phototherapy and/or ph otoch em otherapy ), duration of exposure, and the r eason for
discontinuation of eac h therap y;
presence of psoriatic arthritis and the date of first diagnosis ( bya physician ).
6.2.3 Smoking history
The current and/or pr evious use of tob acco produc ts will be r ecorded , aswell as the est imated 
numberof pa ck- years based on the approximate consumption peryear. Non-smokers will be 
advisedtonot start sm oking during the stud y.

[COMPANY_001] Confidential Page 50
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
6.2.4 Alcohol use history
Thecurrent and/or pr evious use of alcohol w ill be r ecorded. This includes the estimated number 
of alcoholic drinks consumed on average perday, and the date alcohol was last consumed.
Current alcohol use will be assessed throughout the duration of the study  at the 
scheduled visits as indicated in Table 6 -1.
6.2.5 Comorbidities –cardiovascular history
Any information pertaining to car diovascular medical his tor y a ssess edprior to rando mization 
should b e reported on the Cardiovascular History  eCR F.
Additionally , family history  of certain cardiovascular disease s will also be collected .
6.2.6 Relevant medical history  / Current medical conditions
Relevant medi cal his tory/current medical conditio ns, not including psoriasis or psoriati c a rthritis,
will be r ecorded o n the Medical His tory eCRF. 
Relevant medi cal his tory/current medical condition s will include data up to six months prior to
signing of the informed conse nt.W henever p ossib le, diagnoses (and no t symptom s)w ill b e 
recorded.
Significant findi ngs t h atare observ ed after the subject hasprovided inform ed consen t, a nd that
meet the definition of an A E,must b e recorded on the Adverse Event eCR F.
Investiga tor s will have the discretion to r ecord abnormal test fin dings on the Medical Histor y 
eCR
F when in their judgment, the test a bnormality occurred prior to the informed consen t 
s
ignatur e.
6.2.7 Prior and concomitant medications
C
oncomitant medi cation s and prior medi ca tions taken over the sixmonth s preced ing stud y 
e
nrollment wi llbecaptured at th e Screening visit, and updated at Visit 2/Baseline .
6.2.8 Determination of tuberculosis status
Deter mination oftuberculosis (TB) status will berequired before adm
inistration ofstudy  
treatment. TBstatus must bedeter mined by[CONTACT_268299] ,signs, s ymptom s,and TBtesting 
(QuantiFERON -TB G
oldassay ).Anysignif icant findings will be recorded intheappropriate 
eCRF(s), asnecessary .
Ifthe QuantiFERON -TB Gold Assay test ispositive or indetermin ate,aTB workup
should beperformed asdefined byl
ocal guidelines todetermine thesubject ’s TB status.

[COMPANY_001] Confidential Page 51
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
QuantiFERON TB -Gold In -Tube assay
AQuantiFERON®TB-Gold In-Tube a ss ay w illbe performed toass ess the TB status a t screening
for all subject s. This test w il l only be used to deter mine subject ’s eligib ility for th e trial. T hetest
will be used to scr een the subject population for latent tuberculosis inf ec tion ( Dohert y, Van 
Vorhees and Lebwohl l 2008 ).
This bl ood-based a ssay is specific for Mycob acter ium tuberculosis and is not in fluen ced b y 
previ ou sBacillus Ca lmette-Guérin vaccination or exp osure to other Mycobacteria specie s.
T
his test, in contras t t o the purified protein derivative ( PP D)skin test, is also ins ensitive to a 
booster e ffect since the subject is not exposed to the v ac cine. The a ssay measures th e production
o
f interferon-ga mma and presents it relative toa negative and a positive contro l sample
(Manuel and Kumar 2008).
TheQuantiFERO N®-TB Gold assay test wi llbe supp liedby[CONTACT_2237]. Details on the
collection, shipment of samples and reporting of results by[CONTACT_260526] y a r e provided in
t
he Laboratory Manual.
T
heresults of a TB workup forasubject with apositi ve or i ndeter minate tes t mustberecorded
i
nthe eCRF.
If the tes t result is negat ive , the subject may b e randomized
If the tes t result is p ositive , the I nvestigator should perform a TB w orkup for the tes t result as 
perl
ocal pro cedu res.
Subject spositivef
or latent TB perworkup may be rando mizedto the trial i f sufficient
treatment has been initiated acco rd ing to local rou tine c linical pr actice and will be
maintai nedfor the prescrib edduration.
Subject spositivef
or active TB perworkup are not eligible for the st udy.
Subject snegat ivef or TB (no signs of latent or active TB) per workup may b e r andomize d
to the tria l.
I
f the tes t result is inde t erminate, it is recommended to rep eat the tes t once. Th e 
Investiga tor may decide to skip the repetition of the test and pro ceed directly to th e workup
(however this is not reco mmend ed). If a TB wor kupwasconducted prior toscreening, results
from t
he workup canbe us edtoassess e ligibilityifthe wor kup was conducted within 12 
week
s priorto randomization.
If the second test is nega tive, th e subject may b e rando mized.
If the second test is p ositive or indeter minate, the Investigator should perfor m a TB 
workup asperlocal guidelines. The subject w ill no t be eligible for rando mizat ion if : 
“act
ive tuberculosis is presen t”,o r if “latent tu berculosis is p resent” and i s untr eated as
perlocal g uidelines.
Refer toSection 13 (Appendix 2) to see a schematic of the tuberculosis screening 
process and subject eligibility with respe cttoTBtesting.

[COMPANY_001] Confidential Page 52
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_391009] s include (all labs are central exc ept 
w
here indicated) (see also Table 6-1):
vital signs, hema tology , c linical chemistry, viral serology  (HIV, Hepatitis B and Hepatitis 
C), serum pregnancy , phy s ical examination, height, wei ght; P AS I, IGA mod 2011 ; 
DLQI .
6.[ADDRESS_391010] s will be provided with a Self-Administration Log at Visit 8/Week [ADDRESS_391011] s will also be 
instructed to return all used/unused study  treatment and packaging to the study  site at each visit as 
part of the compliance check. At the final study visit (Visit 14/Week 52), the subject ’s Self-
Administration L og will be retained in the subject ’s source documents. 
The Investigator/qualified sitestaff should promote compliance by[CONTACT_317613], totak
ethestudy treatments exactly asprescribed, and by 
[CONTACT_317614] .
Additionall y, sites will be instructed to contact [CONTACT_317615]-home dosing to check compliance and to ensure completion of the Self-
Administration Log. Likewise, subject sshould be instructed to contact [CONTACT_941]
I
nvestigator/qua lified site staff ifhe/she isunable forany reason toattend astudy visit as
scheduled, orifhe/she is unable for anyreason to take the study treatmentathome asprescribed.
6.4 Efficacy
The primary  efficacy  variable is the change from baseline in the target 
(arterial vascular uptake) 
to background (venous blood pool) ratio from the aorta . The primary  analysis time point will be 
at Week 12.
The secondary  efficacy  variables are the following:
Change from baseline in cardiometabolic biomarkers (cardiometabolic function [lipid particle 
size, HDL  function (cholesterol efflux)], measures of inflammation [TNF -Alpha, IL -6, C-
reactive protein , GlycA],adiposity  [leptin and adiponectin], insulin resistance [insulin 

[COMPANY_001] Confidential Page 53
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
levels/glucose to y ield HOMA -IR], and markers predictive of diabetes [apolipoprotein B, 
ferritin, IL-2 receptor A, IL-18, and fetuin -A])
PASI  75 response (y es, no)
PASI  90 response (y es, no)
PASI  100 response (y es, no)
IGA mod 2011 score of 0 or 1 (y es, no)
Change from baseline in DLQI total score
All efficacy  assessments should be performed prior to the administration of study  treatment and 
at all scheduled stud y visits as indicated in Table 6 -1. 
Patient Reported Outcomes (PRO)
PROs should be collected prior to the Investigator performing an y efficacy  assessments:
DLQI
Efficacy  assessments (Investigator)
The following efficacy  assessments 
performed by [CONTACT_317616] s:
PASI
IGA mod 2011
6.4.1 Target (arterial vascular uptake) to background (venous blood pool) ratio 
from the aorta
Subjects will undergo vascular inflammation imaging assessments with full-body  FDG -PET/CT 
scans at three scheduled visits –Visit 2/Baseline, Visit 8/Week 12 and Visit 14/Week 52 (see 
Table 6-1). The FDG -PET/CT scans will be conducted at each investigative site’s local imaging 
center and the whole process should take approximately  [ADDRESS_391012] ’s glucose 
level will be checked by [CONTACT_317617] 150 mg/dL .If the glucose level exceeds 150 mg/dL , consultation with the Medical 
Monitor prior to the imaging will be required to determine if the subject is eligible to continue in 
the study . The whole- body  PET/CT scan will be initiated approximately  120 minutes (± 10 
minutes) after intravenous administration of [18F] -fluorodeox yglucose (FDG).
Within approximately  24 hours after the completion of the FDG -PET/CT scan, the local nuclear 
medicine personnel will issue a clinical report determin
ingif the subject has any clinicall y 
significant findings which would preclude the subject’s continued participation in the study .
The arterial uptake of FDG will be measured by[CONTACT_317618] (SUV )max 
divide dby [CONTACT_65793] (Mehta et al 2012 ). This will yield a target to background ratio 

[COMPANY_001] Confidential Page 54
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
(TBR) which is considered the standard reporting variable in FDG -PET/CT vascular studies. The 
PET/CT images obtained from each site’s local imaging center will be de-identified and should 
be sent to the  I
maging L ab within 1-3 days where trained nuclear 
medicine p ersonnel will undertake a qualitative review of the PET /CT images. During this review, 
two-dimensional (2D) circular regions of interests (ROIs) will be manually  placed on the PET 
images around the external aortic contour, around the hepatic margin, and around articular spaces 
on all transverse slices passing through these structures using low
-dose CT images for anatomic 
guidance. The images will then besent to the central core 
Imaging L abfor measuring the SUVs . The  central PET/CT readers will be blinded to time 
and treatment via Digital Imaging and Communication in Medicine ( DICOM )file editing applied 
by [CONTACT_941] .
The mean aortic SUV will be calculated for five segments of the aorta: ascending aorta, aortic 
arch, descending thoracic aorta, suprarenal abdominal aorta, and infrarenal abdominal aorta. 
These segments are defined to consider separately  various regions of aortic disease that are 
associated with different clinical phenoty pes (e.g., aortic arch disease with stroke, abdominal 
aortic disease with abdominal aortic an eurysm).
6.4.2 Cardiometabolic biomarkers
The following cardiometabolic biomarkers will be anal yzed centrally  at an anal ytical laboratory :
Cardiometabolic function: lipid particle size, HDL function (cholesterol efflux);
Inflammation: TNF- Alpha, IL -6, C- reactive protein , Gly cA;
Adiposity : leptin and adiponectin;
Insulin resistance: insulin levels/glucose to y ield HOMA -IR;
Markers predictive of diabetes: apolipoprotein B, ferritin, IL-[ADDRESS_391013] for a minimum of 8 hours prior to the blood draw for the 
cardiometabolic biomarkers at the foll owing visits only :
Visit 2/Baseline
Visit 8/Week 12
Visit 14/Week 52.
A laboratory  manual will be provided by [CONTACT_317619], handling and shipment.

[COMPANY_001] Confidential Page 55
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
6.4.3 Assessment of total body surface area (BSA ) and Psoriasis A rea and 
Severity Index (PA SI)
The Investiga toror trained qua lifi ed designee will complete the PA SIassessmen t at scheduled 
visits as indicated in Table 6-1. Whenever possible, the same evaluator sh ou ld perfo rmthis
a
ssessment at al l study visits for a given subject . The Investigator is only responsible for 
collecting the components or scoring signs and total regional area. PASI  calculations, including 
changes over time, will be done 
electronicall y, not by  [CONTACT_737].
The total BSA a ff ected by [CONTACT_317620] p soriasi s will be estimated by [CONTACT_737]/trained 
qualified designee from the percent ages of areasaffected,includi nghead, t runk, upper limbsa nd
lowerlimbs (s eebelow for fu lldetails of the PASI a ssessment). The following calculation s wil l
be don e electronically : Eac h reported per centage will be multipli edby[CONTACT_317621] b ody region
corresponding f actor (h ead=0.1, trun k=0.3, upper limbs=0 .2, lo wer limbs=0 .4). The resulti ng
f
our per centageswillbeadded upto estimate the total BSA a ffected by [CONTACT_268307].
APASI score (Fredriksson and Pettersson 1978, Weisman et al 2003 ,Gottlieb et al 2005 )will be
derived asindicated inTable 6-3. The head, trunk, upper li mbs and lower limbs are 
assessed separatel yby [CONTACT_737]/trained qualified designee forerythema ,thickening
(plaque elevation, induration), and scaling (desqua m ation). The average degree ofseverit y of
each sign ineach ofthefour body regions isassigned ascore of 0-4. The area covered by
[CONTACT_317622] a percentage of thetotal area ofthatparticular body
region. The following practical details help the assess ment:
1. The neck is a ssessed as part of the h ead
2. The axillae and groin are a ssessed as part of the tr unk
3. The butto cks are a ssessed as part of the lo wer limbs
4. When scor ing the severity of erythema, scales sh ould not b e removed.
Becau se the h eadand n eck, upper limbs, trunk andl o wer limbs co rrespond toapproximatel y 
10%, 20%, 30% and 40 % of the b ody surface area, respectively, the PASI score is calculat ed 
electronically within the eCRF using the following f ormul a:
PASI = 0.1(E H+ I H+D H)AH+ 0.2(EU+IU+D U)AU+ 0.3(ET+IT+D T)AT+ 0.4 (EL+ I L+D L)AL
The keys for the le tt ers are provided in Table 6 -2.
PASI scores canrange from a lower value of 0, corresponding tonosigns of psoriasis, up toa 
theoretic maximum of 72.0.
T
he baseline value for analysis of the PASI is co lle cted at Visit 2/Baseline . A copy of the PASI is 
provided in Section 13 ( Appendix 3 ).

[COMPANY_001] Confidential Page 56
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Table 6-2 PASI scoring sy stem
Body region Erythema (E) Thickening -
plaque elevation, 
induration (I)Scaling –
desquamation 
(D)Area score –
based on true 
area % ( A)*
Head (H)†0=none 0=none 0=none 0=no involvem ent
1=slight 1=slight 1=slight 1=>0-<10%
2=moderate 2=moderate 2=moderate 2= 10-<30%
3=seve re 3=seve re 3=seve re 3=30-<50%
4=veryseve re 4=veryseve re 4=veryseve re 4=50-<70%
5=70-<90%
6=90-100%
Trunk (T)‡0=none 0=none 0=none 0=no involvem ent
1=slight 1=slight 1=slight 1=>0-<10%
2=moderate 2=moderate 2=moderate 2= 10-<30%
3=seve re 3=seve re 3=seve re 3=30-<50%
4=veryseve re 4=veryseve re 4=veryseve re 4=50-<70%
5=70-<90%
6=90-100%
Upper 0=none 0=none 0=none 0=no involvem ent
limbs(U) 1=slight 1=slight 1=slight 1=>0-<10%
2=moderate 2=moderate 2=moderate 2= 10-<30%
3=seve re 3=seve re 3=seve re 3=30-<50%
4=veryseve re 4=veryseve re 4=veryseve re 4=50-<70%
5=70-<90%
6=90-100%
Lower 0=none 0=none 0=none 0=no involvem ent
limbs (L)§1=slight 1=slight 1=slight 1=>0-<10%
2=moderate 2=moderate 2=moderate 2= 10-<30%
3=seve re 3=seve re 3=seve re 3=30-<50%
4=veryseve re 4=veryseve re 4=veryseve re 4=50-<70%
5=70-<90%
6=90-100%
*Percentage ( not score) of body regio n (not w hole body) affecte d will b e entered in th e eCRF†Neckis assesse d aspartof the Head (H)body regi on
‡Axillaeand groin areassesse d aspartof the Tr unk (T) body r egion
§Buttocks a re assessed aspartof the Lower limbs (L) b ody r egion
Definitions of efficacy variables based on PA SI
The following d efinitions w illbe u sed in th is st udy based on the CHMP guidelines fo r 
psoriasis ( CHMP/EWP/2454/02 2004 ) :

[COMPANY_001] Confidential Page 57
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
PASI 75 response :subject sachieving ≥75% im provement (reduction) in PA SIscore 
compar edtobaseline are defi nedasP A SI75 responders
PASI 90
response :subject sachieving ≥90% im provement (reduction) in PA SIscore 
compar edtobaseline are defi nedasP A SI90 responders
PASI 100
respons e/remiss ion: complete cl earingof psoriasis (PASI= 0)
6.4.4 Investigator’s Global A ssessment (IGA  mod 2011)
T
he IGAmod [ADDRESS_391014] 2 points on the I GAscale ata given t ime 
point compared to thei r s core at Rando mization(Baseline).
The I GAmod [ADDRESS_391015] ’s 
disease state at the t ime of the assessments, and does not attempt a comparison with a nyof th e 
subject ’s previ ous disease states, whether at baseline or at a pr evi ous visit.
T
he IGAmod [ADDRESS_391016] clear Normal to pi[INVESTIGATOR_317586] n of lesi ons; n o thickening; no to minima l 
focal sc aling
2 Mild disease Pi[INVESTIGATOR_317587]; just detect able to mil d thickening; 
predominantly fin e scaling
3 Moderate disease Dull bright red, cl early disti nguishable erythema; cl early 
distinguishable to moderat e thickening; moderate scal ing
4 Severe disease Bright to deep darkred colorati on; seve rethickening with hard 
edges; seve re /coarse scaling coverin g almost all or all lesions
NOTE: Involvement of the nails is not part of the assessment.

[COMPANY_001] Confidential Page 58
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
6.4.5 Health -related quality of life (HRQoL)
Theimpact of psoriasis on various aspects of the subject ’s health-related quality of life (HRQoL ) 
w
ill be assess edby[CONTACT_317623] w il l beperformed at the scheduled 
study  visits as indicated in Table 6-1:
Dermatology  Life Quality  Index (DLQI)
The qualit y o f life assessment sh ould be completed by[CONTACT_317624] (Investi gator orqualified site staff ) who wi llperform the Investi gator
ass
essments.
Thesubject should be given su fficient s pace and t ime to complete th e paper questionnaire. The
s
tudycoordi nator should check the questionnaire for completenes s a nd encour age the subject to
complete anymissing responses.
Before the subject ’s clin
ical examination, th e I nvestiga tor should review the completed
questio nn aire for responses that may indicat e potential AEs or SAEs. If AEs or SAE s a re
confirm ed, the In vestigator must r ecord the event s as per instructions given in Section 7of the
protocol.
I
nvestiga tor s should not encou ragesubject s to chang e the responses r epo rted in the complete d 
questionnaire.
A cop y of the DLQI is provided in Section 13 ( Appendix 5 ).
[IP_ADDRESS] Dermatology  Life Quality  Index (DLQI)
The Der
matology Life Quality Index (DLQI)isa 10- item general dermatology disability  
index desig nedtoassess healt h-relatedquality oflifeinadult subject swith skin diseases such as
eczema,psoriasi s, acne, and viral warts (Finlay  and Khan, 1994). The m easure isself-
administered and includes domains ofdaily activities, leisure, personal relationshi ps, symptoms 
and feelings, treatment, and work/school. The measure is widel y used; it has been tested across 
32 different skin conditions andisavaila blein55languages. The recall period is thelas tweek,
andtheinstrument requires 1to2 minutes forcompletion.
Each item has four response categories, ranging from 0 (not at all) to 3 (very  much). "Not 
relevant" isalso avalid respon seandisscored as0.The DLQItotal score isa sum of the 10
questions. Scores range from 0
to 30 and higher s c ores indicate greater healt h-related 
qualit y
-of-life i mpairment. Additionally ,each subsc aleoftheDLQI may beanalyzed separ ately.
TheDLQI questionnaire (date ofpublication 1994) willbecompleted by[CONTACT_317625] 6-1.
6.4.6 Appropriateness of efficacy  assessments 
The primary  efficacy  assessment is aortic vascular inflammation measured by [CONTACT_6789]-PET/CT, an 
important imaging biomarker and surrogate marker for future vascular risk. FDG -PET/CT is 

[COMPANY_001] Confidential Page 59
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
reliable and predictive of future vascular events independent of other cardiovascular biomarkers, 
and improves rapi[INVESTIGATOR_375]  (i.e.,within four weeks) with interventions known to reduce vascular risk 
(i.e.,statins). It is increasingl y used as a surrogate marker for novel agents being studied in FDA 
regulated trials assessing novel strategies for CV risk reduction. Alternative assessments such as 
carotid IMT and MRI -based measures of wall thickness change only slowly  and thus would 
require longer term trials in which use of placebo would not be feasible. Secondary  efficacy  
assessments include biomarkers that are well established markers of inflammation and 
cardiovascular risk.
The PASI score isastandard andvalidated m easurem entforchronic plaque psoriasis.
The I GA mod 2011 scale has been devel op edby[CONTACT_5343] i n collaboration with health
authorities, in particul arthe FDA. It is based on the previous version of the scale which was used
inthe Phase II s ecukinumab studies. In the modified scale, the two “very severe” and “severe”
categories h
ave been conden s ed into a single category of“severe ”,and th e 
explanations/descriptions of the points on the scale have been im proved to ensure appropriat e 
d
ifferentiation betw een the points.
6.[ADDRESS_391017] be performed prior tos t udy treatment
administration. Appropriate safet y assessments (e.g., evaluation of AEs and SAE s including 
injection site reactions ) should b e repeated afte r d osing with study treatmen t.
Safet y assessments will be performed as indicated in Table 6 -
1:
Evaluation of all AEs and SAEs (including injection site reactions and occurrence of 
infections)
Physical examination
Vital signs
Height and weight
Laboratory  evaluations
Hematology
Clinical chemistry
Viral serology
Pregnancy  and assessments of fertility .
6.5.1 Physical examination 
A complete physical examination will be performed by a  professionally  trained physician or 
health professional licensed to perform physical examinations, and listed on 
FDA Form 1572. 
The physical examination, including general appearance, will be performed at the scheduled 
study  visits as indicated in Table 6-1 . 

[COMPANY_001] Confidential Page 60
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
If indicated, based on medical history  and/or symptoms, additional exams may b e performed at
t
he discretion of the Investiga tor/qualified site staff.
Ifpossible, assess ments for ani
ndividual subject should beperfor med by[CONTACT_317626]/qualified sitestaff throughout thestudy .
Information for all physical examinations must b e i ncluded in the sou rce do cumentation at th e 
study site. Significant findi ngst h atare present prior to the subject s igning inform edc onsen t 
must be included in the Medical His tory e CRF. Significant find ing s made after the signing of
t
he informed consent which m eet the definition of an AE must b e recorded in the subject ’s 
Adverse Event e CRF ( Section 7).
6.5.2
Vital signs
Vital signs(includi ng blood pr essure andpulse measurement s) will beassessed at scheduled
study  visits as indicated in Table [ADDRESS_391018] fiveminutes, with b acksupport eda nd both fe et
placed o n the fl oor, sys tolic and dias tolic bl ood pre ssure (BP) will b e measured using a
validateddevicewith anappropriately si zedc uff. In case the cuff sizes available are not lar ge
e
nough for the subject ’s ar m circumferen ce, a sphygmomanometer with an appropriately si zed
c
uff may b e used. The BP measurement will be r ecorded in the Vital Signs eCRF.
I
f possible, asse ss ments sh ould be performed by [CONTACT_317627].
Normal bl ood pre ssure wi llbe d efined asa sys tolic pre ssure of 90 to<120 mmHg, and a 
diasto lic bl ood pre ssure of 60 to <80 mmHgunder t he m easurement conditions out lined 
above. Notable bl ood pre ssure w ill be hypertension (sys toli c blood pre ssure of ≥140 mmHg 
and/
or dias toli c blood pre ssure of ≥90 mmHg) o r hyp otension (sys tolic bl ood pre ssure o f 
<90 mmHgand/or a dias toli c blood pre ssure of <60 mmHg ). A bl ood pre ssure indi cative o f 
prehyper tension (sys tolic blood pre ssure o f 120 to <140 mmHg and/o r diastolic bl ood pre ssure
o
f80 to <90 mmHg) willnot b e regar dedasnotable ( Chobanian et al 2003 ).
A norma l pulse rate wi llb e defined asa rate of 60 to100 b eats perminute (bpm) under th e 
m
easuremen t c ondition s outlined abov e. Notable pulse r ate s are a rate belo w 60 bp m 
(brady cardia) or above 100 bpm (t achycardia).
Whether action n eeds to be ta ken toaddress not abl e vital sign s values willbe decidedby[CONTACT_12226] , t aking into account th e o verall status of th e subject . No specific actio n is foreseen
aspart of the st udyprotocol.
6.5.3 Height and weight 
Height and body  weight (in indoor clothing but without shoes) will be measured at scheduled 
study  visits as indicated in Table 6-1. If possible, body  weight assessments should be performed 
using the same 
scale throughout the study .

[COMPANY_001] Confidential Page 61
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
6.5.4 Laboratory  evaluations 
A central laboratory  will be used for anal ysis of all specimens collected. Details on the collection, 
shipment of samples, and reporting of results by [CONTACT_317628].
RefertotheLaboratory Manual for ide ntif ication oflaborat ory re ference ra nge values, notable 
values, andthe schemaf or notification ofsitestaffand[COMPANY_001] for out of rangevalues.
Section 13 ( Appendix 1) shows theexpanded laboratory ranges and the clinically  notable 
abnormalities of key  laboratory
 tests.
[IP_ADDRESS] Hematology
Hemoglo
bin, hema tocrit, red bl oodcell count, white bloodcell count with di fferentia l 
(neutrophils includi ngb ands, lymphocytes, monocytes, eosinophils, basophils) and platel et
c
ount will be m eas ured at scheduled study visit s as indicated i nTable 6 -1.
[IP_ADDRESS] Clinical chemistry
Blood urea, creatinine, total 
bilirubin, ALT (SGPT), AST (SGOT), GGT, alkaline phosphatase , 
and hemoglobin A1c(HbA1c) will be measured at scheduled study  visits as indicated in Table 6-
1; HbA1c will be measure d at screening onl y .
[IP_ADDRESS] Fasting laboratory  evaluations
Fasting (8 hour duration with water ad libitum ) laboratory  tests will be performed at screening 
and will include:
Plasma glucose
[IP_ADDRESS] Viral serology
Viral serology  will be performed at screening and will inclu de:
Hepatitis screening: Hepatitis B surface antigen (HBsAg) ; Hepatitis C virus antibody  
(HCVAb)
HIV screening: HIV 1/[ADDRESS_391019] “non- reactive” serology  results at screening. 
6.5.[ADDRESS_391020] during s
creening isnot e ligiblef or randomi zatio n.

[COMPANY_001] Confidential Page 62
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Starting atVisit 2/Baseline ,allwom enexcept those who aresterile or post-menopausal will 
have alocal urine pregnancy testatscheduled study  visits as indicated inTable [ADDRESS_391021] s entered into this study .
7 Safety  monitoring
7.1 Adverse events
An adverse event (AE) is any  untoward medical occurrence (i.e., any  unfavorable and unintended 
sign [including abnormal laboratory  findings], symptom or disease) in a patient or clinical 
investigation subject after providing written informed consent for participation in the study . 
Therefore, an AE may or may not be temporally  or causall y associated with the use of a 
medici nal (investigational) product. Study  treatment includes the study drug under evaluation and 
the comparator treatment or placebo that is given during any phase of the study . Medical
conditions/diseases present at the time of screening areonly conside redAEsifthey worsen
after the 
subject has signed informed consent.
For all subj ects who sign informed consent and who are randomized into the Double- blind 
Treatment Period ofthe studywill have all adverse events that occur after inf ormed consent
is signed r ecorded on the Adverse Event CRF.
The occurrence of adverse events should be sought by [CONTACT_105]-directive questioning of the subject at 
each visit during the study . Adverse events also may be detected when they are volunteered by 
[CONTACT_144970], laboratory  test, or other 
assessments.
Abnormal laboratory  values or test results constitute adverse events onl y if they  fulfill at least one 
of the following criteria:
they induce clinical signs or sy mptoms ;
they are considered clinically  significant ;and/or
they require therapy . 

[COMPANY_001] Confidential Page 63
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_391022] results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typi[INVESTIGATOR_131535]. Investigators have the responsibility  for managing the safet y of individual 
subject and identify ing adverse events. Alert ranges for labs and other test abnormalities 
are 
included in Appendix 1 .
Adverse events should be recorded in the Adverse Events eCRF under the signs, symptoms or 
diagnosis associated with them, acc ompanied by  [CONTACT_6644]
:
Severity  grade 
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
Relationship to the study  treatment
Duration (start and end dates or if continuing at final exam)
Whether it constitutes a serious adverse event (SAE - See Section 7.2 for the definition of 
SAE)
Action taken regarding study  treatment
Concomitant medication(s) taken or non -drug therapi[INVESTIGATOR_111056]
Outcome .
Once an adverse event is detected, it should be followed until its resolution or until it is judged to 
be permanent . An assessment should be made at each visit (or more frequently , if necessary ) of 
any changes in severit y, the suspected relationship to the study  treatment
, the interventions 
required to treat it, and the outcome.
Information about common side effects alread y known about the study drug can be found in the 
Investigator Brochure (IB) or will be communicated between IB updates in the form of 
Investigator Notifications (INs) . This information will be included in the subject informed 
consent and should be discussed with the subject during the stud y as needed.
7.2 Serious adverse events
7.2.1 Definition of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the following 
criteria:
is fatal or life-threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect

[COMPANY_001] Confidential Page 64
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify  what this includes)
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
social reasons and respi[INVESTIGATOR_37207] ’s general 
condition
is medically  significant, i.e. defined as an event that jeopardizes the subject or may require 
medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medicall y significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if more sever e (see Annex I V, ICH-E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediatel y 
life threatening or result in death or hospi[INVESTIGATOR_37208]. Examples of such events 
are intensive treatment in an emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_317588] (see Annex IV, ICH-E2D Guideline).
Any suspected transmission via a medicinal 
product of an infectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the eCRF, SAEs also require individual 
reporting to DS&E as per S ection 7.2.2.
7.2.[ADDRESS_391023] be submitted 

[COMPANY_001] Confidential Page 65
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
within 24 hours of the Investigator receiving the follow -up information. An SAE that is 
considered completel y unrelated to a previously  reported one should be reported separatel y as a 
new event.
Information about all SAEs (either initial or follow up information) is collected and recorded on 
the paper Serious Adverse Event Report Form. The Investigator must assess the relationship to 
each specific component of study treatment (if study treatment consists of several drugs)
complete the SAE Report Form in English, and send the completed, signed form by  [CONTACT_87109] [ADDRESS_391024]
continued or withdrew from study  participation. Each re -occurrence, complication, or progression 
of the original event should be reported as a follow -up to that event regardless of when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the investigational treatment a Drug Safet y and 
Epi[INVESTIGATOR_317589] r for Health Authority  reporting. [COMPANY_001] may need to issue an Investigator 
Notification (IN) to inform all Investigators involved in any study  with the same investigational 
treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with EU Guidance 2011/C 172/[ADDRESS_391025] 
be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termina tion, details of the 
birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded on the Clinical Trial Pregnancy  Form and be reported by [CONTACT_3786] /qualified site staff to the local [COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_18540]. 
Pregnancy  follow -up should be recorded on the same form and should include an assessment of 
the possible relationship to the s tudy treatment .
Any SAE experienced during th e pregnancy  must be reported on theSAE Report F orm.

[COMPANY_001] Confidential Page 66
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
8 Data revie w and database management
8.1 Site monitoring
At a site initiation visit or at an investigator’s meeting, a [COMPANY_001] representative will review the 
protocol and eCRFs with the Investigators and their staff. During the study , [COMPANY_001] employ s 
several methods of ensuring protocol and GCP compliance and the quality/integrit y of the sites’ 
data. The field monitor will visit the site to check the completeness of subject records, the 
accuracy  of entries o n the eCRFs, the adherence to the protocol and to Good Clinical Practice, the 
progress of enrollment, and to ensure that study  treatment is being stored, dispensed, and 
accounted for according to specifications. Key investigator staff must be available to assist the 
field monitor during these visits.  Continuous remote monitoring of each site’s data may be 
performed by  a CRO. Additionally , a CRO may analy ze data and identify  risks andtrends for site 
operational parameters, and provide reports to the Novart is Clinical Team to assist with trial 
oversight.
The Investigator must maintain source documents for each subject in the study , consisting of case 
and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laborato ry data, electrocardiograms, and the results of any  other tests or assessments. 
All information on eCRFs must be traceable to these source documents in the subject 's file. The 
Investigator must also keep the original informed consent form signed by [CONTACT_423] (a signed 
copy  is given to the subject ).
The Investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the eCRF entries. [COMPANY_001] monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of 
SAEs, and of data that will be used for all primary  variables. Additional checks of the consistency  
of the source data with the CRFs are performed according to the study -specifi c monitoring plan. 
No information in source documents about the identity  of the subject s will be disclosed.
8.2 Data collection
Designated investigator staff will enter the data required by [CONTACT_221995] (eCRFs) using fullyvalidated software that conforms to US [ADDRESS_391026]
data for archiving at the investigational site.

[COMPANY_001] Confidential Page 67
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_391027], which employ s the Anatomical Therapeutic Chemical classification system. Concomitant 
procedures, non-drug therapi[INVESTIGATOR_317590] (MedDRA) terminology .
Laboratory  samples (including cardiometabolic biomarkers) will be processed centrall y and the 
results will be sent electronically  to a designated CRO.
FDG -PET/CT scans will be read and analyzed centrally  and the results will be sent electronically 
to a designated CRO.
A PRO questionnaire will be complet ed by [CONTACT_317629], and the data transcribed into the 
eCRF by  [CONTACT_317630].
Randomization codes and data about all study  drug(s) dispensed to thesubject will be tracked 
using an Interactive Response Technology  (IRT). The system will be supplied by a vendor, who 
will also manage the database. The database will be sent electronicall y to a designated CRO.
Each occurrence of a code break via IRT will be reported to the clinical team and monitor.  The 
code break functionality  will remain avai lable until study  shut down or upon request of [COMPANY_001]. 
The occurrence of relevant protocol deviations will be determined. After these 
actions have been 
completed and the database has been declared to be complete and accurate, it will be locked and 
the treatment codes will be unblinded and made available for data analysis. Any changes to the 
database after that time can only  be made after written agreement by  [CONTACT_232141].
8.[ADDRESS_391028] Research Organization will perform the statistical analy sis.
.

[COMPANY_001] Confidential Page 68
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS [ADDRESS_391029] a two-sided alternative 
hypothesis, employ ing a significance level of 0.05.
Efficacy , safet y, and other data will be summarized.  For continuous variables, summary  stati stics 
(mean, standard deviation, median, 25th and 75th percentiles, interquartile range, minimum, and 
maximum) at each time point and for change from baseline to each time point will be reported by 
[CONTACT_1570].
9.1 Analysis sets 
The following analysis sets will be used for the statistical reporting and analy ses:
Randomized Set: 
The randomized set includes all subjects who were randomized.
Safety  Set: The Safet y Set includes all subjects who received at least one dose of study  
medication.  Subjects will be analyzed according to treatment received.
Full Anal ysis Set:  The Full Anal ysis Set includes all subjects to whom study  medication has 
been assigned.  Subjects inappropriately  randomized (e.g., IRT was called in error for 
randomization of a screen failed subject) will be excluded from this analysis set.  Following the 
intent -to-treat principle, subjects will be analyzed according to the treatment they were assigned 
to at randomization.
9.[ADDRESS_391030] to demographic and baseline characteristics for the 
Randomized Set and the Full Anal ysis Set.
9.3 Treatments 
The number of subjects and the length of time (in days) exposed to each treatment will be 
summarized for the Safety  Set.Note that during the Double -blind Treatment Period, all subjec ts 
will receive their last dose of study  treatment at Visit 7/Week 8.
Concomitant medications will be summarized by [CONTACT_268317].
Any condition entered as medical history  or current medical condition at baseline will be coded 
using the MedDRA dictionary  for the Safety
 Set. They  will be summarized by  [CONTACT_317631] .  Summaries for cardiovascular and psoriasis -
specific medical history  will be provided as well.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
9.4 Analysis of the primary  variable
9.4.1 Variable
The primary  efficacy  variable is the change from baseline in the target (arterial vascular uptake) 
to background (venous blood pool) ratio from the aorta.  Target to background ratio is considered 
the standard reporting variable based on FDG -PET/CT scans in vascular studies (see Section 
6.4.1). The primary  anal ysis time point will be at Week 12.
9.4.2 Statistical model, hypothesis, and method of analy sis
Let µjdenote the population mean of change from baseline in the target to background ratio from 
the aorta at Week 12 for treatment group j, j = 0, 
1, where 0 corresponds to placebo and 1 
corresponds to secukinumab.  
The following null h ypothesis (H 0) will be tested against the alternative h ypothesis (H A):
H0: µ1– µ 0= 0 
HA: µ1– µ 0≠0
The primary  efficacy  variable will be analy zed by [CONTACT_317632] (ANCOVA) model 
with treatment , baseline, and body  weight (<90 kg, ≥90 kg) as explanatory variables.  The least 
squares means of the two treatment groups , least squares mean difference of the treatment groups, 
95% confidence interval for the difference in the two treatment groups, and p-value based on the 
fitted linear model will be reported.  
The primary  anal ysis of the primary  efficacy  variable will be based on the Full Anal ysis Set.
9.4.3 Handling of missing values/censoring/discontinuations
Missing data will be imputed using the last-observation -carried-forward (LOCF) method. If a 
subject has no post-baseline value, the missing value will not be imputed and the subject will be 
removed from the anal ysis.
9.4.[ADDRESS_391031] with modified ridit scores (van Elteren’s test), adjusting for 
body  weight (<90 kg, ≥90 kg) ( Stokes, Davis, and Koch, 2012).

[COMPANY_001] Confidential Page 70
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
9.5 Analysis of secondary  variables
9.5.1 Efficacy  variables 
The secondary efficacy  variables are the following:
Change from baseline in each biomarker (see Section 6.4 )
PASI  75 response (y es, no)
PASI  90 response (y es, no)
PASI  100 response (y es, no)
IGA mod 2011 score of 0 or 1 (y es, no)
Change from baseline in DLQI total score
Change from baseline in each biomarker and change from baseline in DLQI  total score will be 
analyzed at each time point using the same ANCOVA model as for the primary  efficacy  variable, 
and missing data will be imputed using the LOCF method.
IGA mod 2011 score of 0 or 1 and PASI 75 / 90 / [ADDRESS_391032] to compare secukinumab and placebo, adjusting 
for body  weight (<90 kg, ≥90 kg) (Stokes, Davis, and Koch, 2012). A 95% confidence interval 
for the difference between the two treatment groups in the proportion of subjects who are 
responders will be calculated using the normal approximation to the binomial 
distribution. For 
response (yes, no) at Week 12 (and other time points), a subject with a missing assessment will 
be considered as a responder (yes) if the subject meets the response criterion at the time of 
premature discontinuation from the study . Otherwise, the subject will be considered as a non-
responder (no).
Analy ses of the secondary  efficacy  variables will be based on the Full Analy sis Set.
9.5.2 Safety  variables 
The assessment of safet y will be based mainl y on the frequency  of adverse 
events and laboratory  
data. Other safet y data (e.g., vi tal signs and special tests) will be considered, as appropriate.
Adverse events will be summarized by [CONTACT_1601], for each treatment group, the number and 
percentage of subjects having any adverse event, having an adverse event in each body  system 
and havi ng each individual adverse event. Any other information collected (e.g., severit y or 
relatedness to stud y medication) will be listed, as appropriate.
Adverse events and serious adverse events up to and including the Week 12 visit will be included 
in the database for the analy sis at the primary  analy sis time point (Week 12).
Laboratory  variables will be summarized. 
Analy sis of safet y data will be based on the Safet y Set.

[COMPANY_001] Confidential Page 71
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
9.5.3 Resource utilization
Not applicable
9.5.4 Pharmacokinetics
Not applicable.
9.5.5 Pharmacogenetics /pharmacogenomics
Not a pplicable.
9.5.6 Other b iomarkers
Not applicable.
9.5.7 PK/PD
Not applicable.
9.6 Interim analy ses
The primary  analysis at Week 12 is considered an interim analy sis. As Week 12 is the primary 
analysis time point, no adjustment to the significance 
level of 0.05 will be made.
9.7 Sample size calculation
The sample size was based on change from baseline in the target (arterial vascular uptake) to 
background (venous blood pool) ratio (TBR) from the aorta.  Using a t -test, a clinically  important 
mean treatm ent difference of 0.15, a (common) standard deviation (SD) of 0.196, an allocation 
ratio of 1:1, a two-sided significance level of 0.05, and a power of 0.90, it was determined that 
approximately  74 subjec ts (37 in each treatment group) are necessary (nQuer y Advisor 7.0) 
(Bissonnette et 
al 2013; Tawakol et al 2013). Without adjusting for multiplicity , the sample size 
of [ADDRESS_391033] 0.90 power for othe r biomarkers (see Section 6.4.2 ) if the 
treatment difference is 0.[ADDRESS_391034] s (42 in each treatment 
group) will be randomized.
10 Ethical considerations
10.1 Regulatory  and ethical compliance 
This clinical study  was designed and shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US 21 CFR, and Japanese Ministry  of 
.

[COMPANY_001] Confidential Page 72
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of 
Helsinki.
10.[ADDRESS_391035] s may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapable of doing so, 
after such consent has been provided by a legally  acceptable representative(s) ofthe subject . In 
cases where the subject ’s representative gives consent, the subject should be informed about the 
study  to the extent possible given his/her understanding. If the subject is capable of doing so, 
he/she should indicate assent by [CONTACT_37249] y signing and dating the written informed consent 
document or a separate assent form. Informed consent must be obtained before conducting any 
study -specific procedures (i.e.,all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the subject source documents. 
[COMPANY_001] will provide to Investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by [CONTACT_317633]/IEC, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC approval.
Wome n of child bearing potential should be informed that taking the study  treatment may  involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order to 
participate in the study  they must adhere to the contraception requirement for the duration of the 
study . If there is any  question that the subject will not reliably  compl y, they should not be entered 
in the study .
10.3 Responsibilities of the investigator and IRB/IEC 
Before initiating a trial, the Investigator/institution should obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (IRB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subject recruitment procedures (e.g., 
advertisements) and any other written information to be provided to subject s. Prior to study  start, 
the Investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to 
conduct the study  in accordance with these documents and all of the instructions and procedures 
found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, 
auditors, [COMPANY_001] Quality  Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs, 
and regulatory  authorities as required. If an inspecti on of the clinical site is requested by a 
regulatory  authorit y, the Investigator must inform [COMPANY_001] immediately  that this request has been 
made.
.

[COMPANY_001] Confidential Page 73
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
10.4 Publication of study  protocol and results 
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and finalization 
of the study report the results of this trial will be either submitted for publication and/or posted in 
a publicly  accessible data base of clinical trial results.
[ADDRESS_391036] be 
considered a protocol amendment, and unless such an amendment is agreed upon by  [CONTACT_317634]/IEC and health authorities, where required, it cannot be implemented. All 
significant protocol deviations will be recorded and reported in the CSR.
11.[ADDRESS_391037] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC prior to 
implementation. Only  amendments that are intended to eliminate an apparent immediate hazard 
to subject s may be implemented immediatel y provided the Health Authorities are subsequently 
notified by  [CONTACT_6670]/IEC is notified. Notwithstanding the need 
for approval of formal protocol amendments, the Investigator is expected to take any immediate 
action required for the safety  of any sub
jectincluded in this study , even if this action represents a 
deviation from the protocol. In such cases, the reporting requirements identified in Section [ADDRESS_391038] .
Abbas A et al. (2015) Interleukin 23 levels are increased in carotid atherosclerosis: possible role 
for the interleukin 23/interleukin 17 axis. Stroke; 46(3):793-9.
Bissonnette R et al. (2013) Effects of the tumor necrosis factor- α antagonist adalimumab on 
arterial inflammation assessed b y positron emission tomograph y in patients with psoriasis: results 
of a randomized controlled trial. Circ Cardiovasc Imaging; 83-90.

[COMPANY_001] Confidential Page 74
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Chobanian AV, Bakris GL, Bl ackHR(2003) Seve nthreport ofthe joint national committee on
prevention, detection, evaluation, andtreatment ofhigh blood pressure. H ype rtension; 42:1206–52.
Commi tteefor medicinal products for human use (CHMP), Euro pean M edicin es Agency fo r t he
Evaluation of Medicines for Hum an Us e.(2004)Gui deline on c lin ical investi gation o f medicinal
products indi catedf or the treatment of p soriasis. CHMP/EWP /2454/02 corr. document. London,
[LOCATION_006]
Doher t
ySD,Van Voorhees A, Lebwohl MG(2008)National psoriasis foundation consensus 
statement on s creening forlatent tuberculosis infectioninpatientswith psoria sistreatedwith 
systemic andbiologicagents. J. Am. Acad. Derm atol; 59(2):209–217.
Erbel C et al. (2014) IL-17A influences essential functions of the monocy te/macrophage lineage 
and is involved in advanced murine and human atherosclerosis. J I mmunol; 193(9): 4344 -
55.
Erbel C et al. (2011) Expression of IL- 17A in human atherosclerotic lesions is associated with 
increased inflammation and plaque vulnerabilit y. Basic Res Cardiol; 106:125 -34.
Figueroa AL, et al. (2013) Measurement of arterial activity  on routine FDG PET/CT images 
improves prediction of risk of future CV events. JACC Cardiovasc Ima ging; 1250-9.
Finla
yAY, KhanGK(1994) Dermatol ogy Life Qua lity Index (DLQI): A si mple practical 
measure forroutine clinical use.Clin ExpDermatol; 19:210 –16.
Fre
driksson T, Pettersson U(1978) Seve repsoriasis—oral thera pywith a new retinoid. 
Dermatol o
gica;157:23 8–44.
Gelfand J, et al (2006) Risk of my ocardial infarction in patients with psoriasis. JAMA; 
296(14):1735
-41.
Gelfand J, et al (2009) The risk of stroke in patients with psoriasis. J I nvest Dermatol; 
129(10):2411-8.
Gottlieb A,Griffiths CEM, HoVC,et al (2005) Efficacyandtolerability of oral pi[INVESTIGATOR_317591]: a double-blind, multicentre,
randomi zeddose-findi n
gtrial. BrJDermatol; 152:1219-27.
Karbach S et al. (2014) Interleukin 17 drives vascular inflammation, endothelial dy sfunction, and 
arterial h ypertension in psoriasis- like skin disease. Arterioscler Thromb Vasc Bio; 34(12):2658 -
68.
Lee SJ, et al. (2008) Reversal of vascular 18F-FDG uptake with plasma high -density  lipoprotein 
elevation b y atherogenic risk reduction. J Nucl Med; 1277-82.
Manuel O,Kumar D(2008) QuantiFE RON- TBGold assa y forthediagnosis of latent tuberculosis
infection. ExpertRevDia gn; 8(3): 247-56.
Mehta N et al. (2012) Quantification of atherosclerotic plaque activity  and vascular inflammation 
using [18- F] fluorodeox yglucose positron emission tomograph y/computed tomograph y (FDG -
PET/CT). J Vis Exp ; 22(63):e3777
.

[COMPANY_001] Confidential Page 75
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
Mehta N, et al. (2012) Abnormal lipoprotein particles and ch olesterol efflux capacity  in patients 
with psoriasis. Atherosclerosis; 218-21.
Mehta N, et al. (2011) Systemic and vascular inflammation in patients with moderate to severe 
psoriasis as measured b y [18F] -Fluorodeox yglucose Positron Emission Tomograph y
-Comp uted 
Tomograph y (FDG -PET/CT). Arch Dermatol ; 1031-39.
Mehta N, et al. (2010) Patients with severe psoriasis are at increased risk of cardiovascular 
mortality : cohort study  using the General Practice Research Database. European Heart Journal; 
1000-6.
Naik H , et al. ( 2015) Psoriasis area severity
 index score positively  associates with vascular 
inflammation by  [CONTACT_38967]/CT. J I nvest Dermatol; (1 35):S35-S35.
National Psoriasis Foundation (2014) Statistics. Available from:
https://www.psoriasis.org/learn_statistics. [18 March 2014].
Ogdie A, et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, 
psoriasis and rheumatoid arthritis: a population- based cohort study . Ann Rheum Dis; 74(2):326 -
32.
Roubille C et al. (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non -
steroidal anti -inflammatory  drugs and corticosteroids on cardiovascular events in rheumatoid 
arthritis, psoriasis and psoriatic arthritis: a s ystematic review and meta -analy sis. Ann Rheum Dis; 
74:480 -9.
Stokes ME, Davis CS, Koch GG (2012) Categorical data analy sis using the SAS sy stem. 3rd ed; 
Cary , NC: SAS I nstitute, Inc.
Tawakol A, et al. (2013) Intensification of statin therap y results in a rapid reduction in 
atherosclerotic inflammation: results of a multi -center FDG -PET/CT feasibility  study . JACC ;
909-17.
W
eisman S,Pollack CR,Gottschalk RW(2003) Psoriasis disease severitymeasures: compari ng
efficacy of t reatments forseverepsoriasis.JDermatolog Treat; 14:158 -65.
Yeung H, et al. (2013) Psoriasis severit y and the prevalence of major medical comorbidity: a 
population -based study . JAMA Dermatol; 149 (10):1173 -9.

[COMPANY_001] Confidential Page 76
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
13 Appendi ces
13.1 Appendix 1: Clinically  notable laboratory  values and vital signs
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory  tests. Notable values for blood pressure and pulse are presented in Section 6.5.2.
Whether or not any action needs tobetaken toaddress notable labor atory orvital signs values
willbe determined by[CONTACT_36705]/qualified site staff, taking intoaccount theoverall status of
thepatient .Nospecific action ispre-defined within this study protocol.
Liver function and related variables
ALT (SGPT) > 3 x Upper Limit of Normal (ULN)
AST (SGOT) > [ADDRESS_391039]
Total bilirubin > 1.[ADDRESS_391040]
Alkaline phosphatase > [ADDRESS_391041]
Renal function and electroly te variables
Creatinine (serum) > 1.[ADDRESS_391042]
Hematology  values
Hemoglobin ≥ 2.0 g/dL decrease from baseline
Platelet count < Lower Limit of Normal (LLN)
White blood cell < 0.[ADDRESS_391043]
Neutrophils < 0.[ADDRESS_391044]
Eosinophils > 1.[ADDRESS_391045]
Lymphocytes: > 1.[ADDRESS_391046]

[COMPANY_001] Confidential Page 77
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
13.2 Appendix 2: Tuberculosis screening flowchart

[COMPANY_001] Confidential Page 78
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
13.3 Appendix 3: Psoriasis Area and Severity  Index (PA SI) and Body  
Surface A rea (BSA )

[COMPANY_001] Confidential Page 79
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
13.4 Appendix 4: Investigator’s Global A ssessment (IGA  mod 2011)

[COMPANY_001] Confidential Page 80
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
13.5 Appendix 5: Dermatology  Life Quality  Index (DLQI)

[COMPANY_001] Confidential Page 81
Amended Protocol Version 03 (Clean ) Protocol No. CAIN457AUS 02
